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   Sterol regulatory element-binding proteins (SREBP) are transcription factors 
that regulate genes involved in lipid metabolism especially in the liver.  Therefore, 
hepatic SREBP is significant regulator of systemic lipid metabolism.  Evidence 
demonstrates that insulin and dietary unsaturated fatty acid (UFA) regulate SREBP1 
expression and subsequent SREBP1-mediated gene transcription, events that in many 
instances result in modulation of systemic fatty acid and triglyceride (TG) homeostasis. 
A series of investigations was designed to uncover novel regulators of SREBP1. Dietary 
and exogenous addition of UFA has been shown to regulate SREBP function; yet, an 
  xiv  
endogenous source of UFA capable of modulating SREBP remains elusive. Group VIA 
calcium-independent phospholipase A2 (iPLA2) releases UFA from the sn-2 position of 
glycerophospholipids.  We hypothesized that iPLA2 provides UFA to suppress SREBP. 
iPLA2 overexpression and inhibition studies were implemented.  iPLA2 inhibition 
increased SREBP1 expression, SREBP-mediated transcription and the expression of 
SREBP1 gene targets in vitro.  In vivo overexpression of iPLA2 resulted in decreased 
expression of SREBP1 protein and plasma triglyceride. In contrast, iPLA2 
overexpression attenuated SREBP1 expression, SREBP-mediated transcription and 
expression of SREBP1 targets genes. These data support the hypothesis that iPLA2 
generates endogenous UFA that limit SREBP function.  Use of a replication-deficient 
adenovirus 5 (Ad-5) expression vector in the iPLA2 study led to the unexpected 
observation of hepatic SREBP1 activation following Ad-5 infection. Because of this 
observation, we tested the hypothesis that replication-deficient Ad-5 might augment 
lipid synthesis in liver. We demonstrate that first generation Ad-5, a ubiquitous 
transgene expression vector, induces expression of SREBP1 and its target genes and 
leads to increases in fatty acid synthesis in vivo and in vitro.  The phosphatidylinositol 
3-kinase (PI3K) inhibitor, PX-866, suppressed Ad-5-induced SRBEP1 expression and 
hypertriglyceridemia implicating the PI3K/Akt pathway in Ad-5 activation of SREBP1. 
Use of PX-866 led to the discovery of a third mechanism of SREBP1 regulation.  In 
vivo studies demonstrate that PX-866 modulates basal lipid metabolism in part through 
decreasing plasma TG, an increased trend toward decreased SREBP1 expression and a 
  xv  
significant increase in plasma cholesterol. These studies characterize three distinct 
novel regulatory mechanisms of SREBP1.
 CHAPTER 1: General Introduction 
 
  
  
 Cellular lipids serve several roles beyond providing a source of energy and the 
building blocks of the cell-membrane architecture (1).  It is now well appreciated that 
lipids themselves greatly impact cellular function and homeostasis as studies provide 
ample evidence that lipids are often bioactive and via intracellular signaling and/or 
endocrine, paracrine or autocrine action are capable of influencing diverse cellular 
processes often facilitated by modulation of gene expression (2-9).  Consequently, 
aberrant lipid metabolism itself plays an etiological role in many disease states 
including diabetes, liver disease, cancer, nervous system dysfunction and 
atherosclerosis (10-15). The investigation of several distinct elements and their 
mechanisms that impact lipid metabolism and/or regulate the expression of proteins 
involved in lipid metabolism is warranted and is the major focus of these studies.  The 
following studies characterize novel regulation of lipid metabolism by first-generation 
adenovirus-5 (Ad-5), commonly used as an expression vector in research (16-19) and 
gene therapy (20); the Group VIA calcium-independent phospholipase A2 (iPLA2), an 
enzyme already appreciated for its roles in lipid metabolism and a novel 
phosphatidylinositol 3-kinase (PI3K) inhibitor PX-866 (21).   
 1
  2  
 
Examples of the influence of lipids on cellular processes and signaling 
Proper cell signaling and function rely on all classes of lipids.  For instance, 
cholesterol-derived steroid hormones diffuse across the plasma membrane to 
subsequently bind intracellular steroid hormone receptors which translocate to the cell 
nucleus and act as nuclear transcription factors (22). Other steroid hormones modulate 
cellular processes that can result in inflammation, suppression of the immune response, 
allergic reactions, proper or improper organ function, blood-pressure maintenance and 
energy mobilization (23).  Cholesterol itself can modulate cellular function and 
homeostasis.  Enrichment of cholesterol in the ER can initiate the unfolded protein 
response (UPR) in macrophages, an event capable of resulting in cell apoptosis (24).  
Cholesterol can also affect transcription via its inhibition of the transcription factor 
sterol regulatory element binding proteins (SREBP), a fundamental regulator of genes 
involved in cholesterol, fatty acid and triglyceride synthesis in the liver and other tissues 
(25). 
The sphingolipids, sphingosine-1-phosphate and ceramide, synthesized via the 
sphingomyelinase (Smase) hydrolysis of sphingomyelin or de novo synthesis (1), are 
highly bioactive and enormously impact cell motility, proliferation and apoptosis, 
survival and cancer cell biology (26;27).  Beyond its prosurvival and mitogenic 
influence, sphingosine-1-phosphate has been implicated as a molecular player in 
immune system function (28), cardiac development and angiogenesis (29).  Ceramide 
on the other hand has been implicated in cell growth arrest (29) the stress response and 
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subsequent results including apoptosis and growth suppression (30).  The cellular 
implications of this lipid are clinically relevant in cancer biology.  Studies demonstrate 
that chemotherapeutic agents often increase levels of ceramide, an event that has 
prompted research into its potential in the treatment of cancer (31).  In contrast, 
sphingosine kinase, responsible for the conversion of sphingosine to sphingosine-1-
phosphate (1), is arguably an oncogene as its generation of sphingosine-1-phosphate 
promotes cell proliferation (32).  
 Like the sphingolipids, glycerophospholipid derivatives are often exceptionally 
bioactive lipids capable of guiding cellular function.  Phospholipase C catabolism of 
phosphatidylinositol-bisphosphate generates diacylglycerol (DAG) and inositol 1,4,5-
triphosphate (IP3) (33;34).  The release of IP3 can induce the release of calcium stores 
from the endoplasmic reticulum (ER), an event central to many cellular processes.  
Released ER calcium facilitates the translocation of protein kinase C (PKC) to the 
plasma membrane where it is activated by DAG and, in turn, can regulate many second-
messenger proteins (34).  Furthermore, there is evidence to suggest a role for IP3-
mediated calcium release in the secretion of insulin from the pancreas (35;36), thus 
implicating a bioactive role for IP3 and lipids in general in the control of glucose levels 
and in the pathology of diabetes. Phospholipase A2 (PLA2) enzymes catabolize 
membrane glycerophospholipids to release unsaturated fatty acid from the sn-2 position 
and a lysophospholipid (37).  Further enzymatic action by lysophospholipase D on the 
lysophospholipid released by phospholipase A2 yields mitogenic lysophosphatidic acid 
(LPA), an extremely potent lipid signaling molecule as virtually all mammalian cells 
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respond to this lipid (38).   Polyunsaturated fatty acid (PUFA) released from the sn-2 
position of membrane glycerophospholipids is bioactive in many respects.  Exogenous 
unsaturated fatty acids, like cholesterol, can modulate SREBP regulation of lipogenesis 
(39), thus providing a role for fatty acid bioactivity in atherosclerosis and lipid 
disorders.  As will be mentioned, PLA2-generated free fatty acid can potentially 
influence lipid metabolism via SREBP.  In inflammatory cells, arachidonic acid 
commonly occupies the sn-2 glycerophospholipid position (40;41).  Following PLA2-
mediated hydrolysis, released arachidonic acid can be further metabolized to produce 
eicosanoids, leukotrienes and other inflammatory mediators (42).  PUFA has also been 
shown to increase sphingomyelinase (Smase) activity resulting in the generation of 
ceramide (43) as well as serving as a ligand for peroxisome-proliferator-activated 
receptors (PPAR) which can impact cancer cell biology and lipid metabolism (44).  
Another phosphoglyceride species, platelet-activating factor (PAF), is potently 
bioactive as it, among other activities, is an inflammatory mediator to which 
macrophages, platelets, neutrophils and other cells respond (45) and plays a role in liver 
damage (46).  While incomplete, these cursory details above underscore the 
significance of lipids to proper—and improper—cell function and can provide an initial 
framework to understanding the etiological role that aberrant lipid metabolism plays in 
many diseases.  The studies presented here will examine the effect of Ad-5, iPLA2 and 
PX-866 on lipid metabolism with an emphasis on SREBP and the liver. 
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Sterol regulatory element-binding proteins 
 Many of the genes encoding proteins involved in fatty acid (FA), triglyceride 
(TG), and cholesterol synthesis contain sterol response elements (SRE) that allow for 
feedback regulation of expression (25;47;48).  SREs promote gene expression when 
bound by sterol regulatory element binding proteins (SREBPs), members of the basic-
helix-loop-helix family of transcription factors.  Genes regulated by mature active 
SREBP include many of the genes encoding proteins involved in the synthesis and 
uptake of cholesterol, triglycerides and fatty acids (25) (Figure 1).  These genes include 
the group VIA calcium-independent phospholipase A2 (49), cholesterol-associated 
proteins such as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA 
reductase), low-density-lipoprotein (LDL) receptor, and squalene synthase, fatty acid-
associated synthesis genes including fatty acid synthase (FAS) and acetyl CoA 
carboxylase (ACC) (50).  SREBPs are characterized by their dual-DNA-binding 
specificity—the ability to recognize both a unique sequence and a common structural 
motif of DNA (51)--and in their initial expression as an immature precursor protein 
bound to the ER.  These transcription factors bind the canonical inverted repeat E-box 
sequence 5’-CAXXTG-3’, typically recognized by bHLHLZ family members and the 
SRE, the direct repeat sequence 5’-TCACXCCAC-3’ (52).   
 The SREBPs are encoded by two genes, generating SREBP1 and SREBP2 
proteins.  The SREBP1 gene has two transcription start sites, which generate two forms 
of SREBP1: SREBP1a and SREBP1c.  In general, SREBP2 regulates genes involved in 
cholesterol synthesis and metabolism, SREBP1c is more closely associated with the 
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synthesis of fatty acids and triglycerides and  SREBP1a induces both families of genes 
when its mature form is over expressed in mouse liver (53;54). SREBP1c appears to be 
the most relevant isoform in vivo especially in the liver and in primary cells while 
cultured cells express primarily SREBP1a .  However, transcriptional activity of 
SREBP1c is less robust than that of SREBP1a, likely due to the truncated acidic domain 
at the N-terminus of SREBP1c. 
The nuclear pool of SREBP is controlled at two levels: expression of precursor 
SREBP protein and processing to its mature, transcriptionally active form (25;48).  
Processive regulation of SREBP has been characterized as follows (25):  In sterol-
loaded cells, SREBP is bound to the membrane of the ER in its inactive precursor form.  
The regulatory domain of approximately 590 amino acids at the SREBP C-terminus 
binds to the SREBP cleavage-activating protein (SCAP) which in the absence of sterols 
associates with COPII proteins, form COPII-coated vesicles and bud from the ER and 
subsequently fuse to the golgi (55;56).  SCAP acts as a sterol sensor.  When sterol 
levels decline, SCAP favors a conformation that dissociates it from the ER resident 
protein Insig and promotes translocation of SREBP1 from the ER to the golgi apparatus 
(57;58).  SCAP and Insig have been shown to bind cholesterol and oxysterols, 
respectively, and the binding of either sterol induces association between the two 
proteins resulting in the retention of SREBP in the ER (59-61).  Recently, Du et al 
demonstrated that Akt activation is required for SCAP to facilitate the translocation of 
SREBP2 and presumably SREBP1 from the ER to the golgi (62).  Two proteases in the 
Golgi membrane designated site-1 protease (S1P) and site-2 protease (S2P) release the 
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N-terminal “business end” of SREBP yielding the processed mature transcription factor.  
This “activated” form of SREBP translocates to the nucleus to effect transcription of its 
target genes.  SREBP processing is an essential event in the regulation of lipid synthesis 
and metabolism in the liver. This event is subject to feedback regulation by both sterols 
and polyunsaturated fatty acids which suppress translocation and processing (39), 
though currently no evidence indicates the ability of PUFA to directly bind SCAP or 
Insig to inhibit SREBP processing. 
  8  
Figure 1:  Gene targets regulated by SREBP in cholesterol and fatty acid metabolism 
(25) 
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Early studies characterizing SREBP  
The use of knockout and transgenic mice led to the characterization of SREBP, 
its targets and highlighted its critical role in lipid metabolism especially in the liver and 
adipose tissue.  Dietary manipulation in mouse and hamster models also contributed to 
the early characterization of SREBP1 and 2 in the liver.  Hamster hepatic SREBP1 and 
2 was shown to decrease in response to a high-cholesterol diet (63).  Hamsters fed a 
low-fat, high-carbohydrate diet showed increases in the transcriptionally active nuclear 
form of SREBP1 (64) whereas in hamsters treated with the HMG CoA synthesis 
inhibitor lovastatin, hepatic, nuclear SREBP2 increased (65).  Although germline 
deletions of SREBP1, which deleted both SREBP1a and Ic, and deletions of SREBP1c 
only resulted in partial lethality, surviving SREBP1 and SREBP1c specific knockout 
mice showed decreased hepatic FAS expression, hepatic FA synthesis and decreased 
circulating TG (66;67).  Because germline deletion of SREBP2, 1c or 1a resulted in 
complete lethality or partial lethality, respectively (25;66-68), the laboratory of Brown 
and Goldstein resorted to a Cre recombinase system in order to disrupt the S1P and 
SCAP genes in adult mice which resulted in adequate inhibition of the transcriptionally 
active nuclear forms of SREBP1 and 2 (68;69).  Analysis of the livers of these knockout 
mouse demonstrated decreased expression of the SREBP targets HMG CoA reductase 
and FAS and a 70 to 80% decrease in fatty acid and cholesterol content.  Identification 
of several mutant Chinese hamster ovary (CHO) cell lines with deficiency in the SIP 
and S2P further support the in vivo results as these mutations created cholesterol 
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auxotrophs incapable of processing SREBP2 and subsequent transcription of its targets 
HMG CoA reductase, HMG CoA synthase and the LDL receptor (50;70-72).   
 Transgenic mice overexpressing nuclear SREBP1a and c and SREBP2 lacking 
the transmembrane domains that tether precursor SREBP to the ER and mice 
overexpressing a dominant-negative SCAP protein support conclusions drawn from the 
aforementioned gene deletion studies (25;50).  Dominant-negative SCAP mice exhibit 
elevated hepatic nuclear SREBP1a and 1c and SREBP2, increased expression of 
SREBP1 and 2 target genes, increased FA and cholesterol synthesis and increased liver 
FA and cholesterol mass (73).  Overexpression of SREBP1a resulted in increases in 
cholesterol and FA synthesis, liver cholesterol and FA mass and increases in cholesterol 
and FA biosynthetic gene expression (54).  Furthermore, due to the extreme increases in 
hepatic lipid mass, these mice developed significantly larger livers.  As expected, 
overexpression of SREBP1c increased FAS gene expression, increased in FA synthesis 
and hepatic FA mass by four-fold whereas overexpression of SREBP2 increased 
cholesterol synthetic gene expression, hepatic cholesterol synthesis and mass with 
moderate elevations in FA and FA synthetic genes indicating a slight ability of SREBP2 
to regulate genes involved in FA metabolism (53;74). 
 
Regulation of SREBP by PUFA 
As mentioned, sterols have been shown to inhibit SREBP processing and thus 
the transcription of its target genes and other studies indicate that  exogenous 
unsaturated fatty acids demonstrate this inhibitory role as well (39;75;76).  Expression 
  11  
of SREBP is thought to be controlled in several ways.  The promoter of the SREBP 
gene itself contains SREs to provide what has been termed a “feed-forward” mechanism 
of regulation (25;77;78).  In addition to sterols, polyunsaturated fatty acids (PUFAs) 
also suppress SREBP processing and translocation (39;43;79). The effect of PUFAs 
appears to be largely specific for SREBP1 (76;80) and therefore effects of PUFAs are 
most apparent on fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and other 
lipogenic genes associated with triglyceride synthesis. SREBP1c expression is another 
target for PUFA, which antagonizes LXR-mediated induction of SREBP1c expression 
(81-84). Proposed mechanisms include reduced LXR binding to the LXR response 
element (LXRE) in the SREBP1c promoter and reduced association with coactivators 
(81;82) in the presence of PUFA, although a recent study suggests that dietary PUFA 
may regulate SREBP1c in a LXR-independent manner (84). To this end, there is also 
evidence that PUFA promote increased turnover of SREBP1c mRNA and proteasome-
mediated catabolism of mature SREBP1c (85;86). Together, these data indicate that 
PUFA likely suppress hepatic lipogenesis by regulating SREBP1c at a variety of levels. 
 
SREBP and insulin signaling 
SREBP1c is also regulated at the expression level by insulin which promotes 
lipogenesis largely through induction of this protein (25;83).  Notably, activation of 
SREBP1c by insulin is crucial to lipid metabolism in the liver (87).  In primary rat 
hepatocytes, inhibition of the PI3K/Akt pathway with LY294002 and wortmannin 
attenuates SREBP1c expression in response to insulin (88).  Further characterizing the 
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activation of SREBP1c expression by insulin is a recent study demonstrating that 
atypical protein kinases C ζ and λ play roles as well (89).  This study found that 
disrupted insulin-activated signaling via atypical protein kinases C ζ and λ results in 
decreased SREBP1c expression. Other studies have further demonstrated that liver X 
receptors (LXR) are essential for basal and as well as insulin-stimulated SREBP1c 
expression (83;90;91). LXR induces SREBP1c transcription by binding to a ACCTCA 
direct repeat (DR-4) together with retinoid X receptor (RXR) (92). Ligand binding 
(LXR: oxysterol; RXR: retinoic acid) induces dissociation of the corepressors SMRT 
and NCor followed by association of coactivators (SRC-1) that drive transcription of the 
SREBP1c gene (93;94).  In addition, the SREBP1c promoter has a SRE that provides 
positive feedback regulation of its expression (95). 
 
Influence of microorganisms on lipid metabolism and the biology of Adenovirus-5 
 A growing body of literature relates viral (96-100), bacterial (101;102), and 
parasite (103)  infections to changes in metabolism, dyslipidemia, fatty liver disease, 
and obesity. For example, enteroviruses, particularly coxsackie B4 virus, target 
pancreatic β  cells, leading to type I diabetes secondary to reduced insulin secretion 
(96;97). Perhaps the best characterized example is that of chronic hepatitis C virus 
(HCV) infection which has been strongly associated with insulin resistance, non-
alcoholic fatty liver disease (NAFLD) and increased expression of lipogenic genes in 
hepatocytes (98;99;104).  Because viral expression vectors are often used for transgene 
expression and gene therapy, the potential for these viral expression vectors, 
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specifically Ad-5 based vectors, to induce aberrant lipid metabolism is an attractive and 
necessary investigation.  
 Since the discovery of the human adenovirus in 1953 (105), an etiological factor 
in upper respiratory tract infection (106), replication-deficient adenoviruses have been 
widely employed for gene transfer in vitro and in vivo studies (20).  While their efficacy 
in gene therapy presents many challenges, adenoviruses are currently used in clinical 
trials to treat cancer, cardiovascular disease and several inherited disorders (20).  
Notably, the potential for a severe immune response as illustrated by the death of Jesse 
Gelsinger is one of several obstacles facing researchers in the field of gene therapy 
(20;107). Another challenge to adenovirus-mediated gene therapy is the ability to target 
specific tissues as most adenovirus serotypes initially associate with the Coxsackie and 
adenovirus receptor (CAR), a receptor expressed broadly among many cell types (20).  
Though modifications to adenoviruses have improved tissue specificity, there is the 
propensity for significant natural tropism of the adenovirus to the liver in vivo (108).  
Adenoviruses have also been employed to study liver function in vivo and may hold 
promise as a vector to treat liver disorders (16;18). 
Unlike retroviruses, adenoviruses do not integrate into the host cell genome.  
Ad-5 and Ad-2 of subgroup C of the adenoviruses are two of the most extensively 
studied adenoviruses and in humans are typically associated with upper respiratory tract 
infections (109).  Crucial to adenovirus structure is the fiber protein containing a distal 
fiber knob that interacts with host cell CAR and the penton base adjacent to where the 
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fiber shaft meets the icosehedral protein capsid.  The penton base contains an arginine-
glycine-aspartate (RGD) motif that interacts with host cell alpha and beta integrins and 
with CAR binding to the fiber knob, the adenovirus enters the host cell (109;110).  
Intracellularly, infection by Ad-5 and other adenoviruses has been shown to activate the 
PI3K/Akt pathway (111;112) 
Of the adenoviruses, Ad-5 is most often employed for transgene expression.  
Ad-5 has a genome consisting of linear double-stranded DNA molecule of 36 kb in 
which transgenes typically are inserted in place of either early gene 1 (E1) and early 
gene 3 (E3) (113).  There are two “sets” or regions of genes in the genome of Ad-5 and 
other adenoviruses.  The early genes are involved in what could be considered 
“priming” the host cell for viral replication whereas the late genes are responsible for 
encoding viral structural proteins(109).  The E1A coding region of E1 interacts with 
host cell transcription factors to facilitate the transcription of other early genes and 
promotes expression of proteins critical to adenoviral replication.  E1B is responsible 
for sequestering p53 to promote cell survival during viral replication.  The E3 region 
acts to suppress the host immune response as well as inhibit host-cell apoptosis (109). 
First-generation Ad-5 used for transgene expression are replication-deficient due 
to deletions in of the E1 region and/or a complete or partial deletion of region E3 (20).  
Studies using these vectors have uncovered several shortcomings of their use.  
Replication deficient Ad-5 was used in clinical trials for the first time to treat cystic 
fibrosis and due to poor transgene expression prompted the use of second generation 
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Ad-5 with E4 deleted or E3 returned to the Ad-5 genome (20;114).   Transgene 
expression using first-generation Ad-5 was shown to be limited with undetectable 
expression occurring at 2 to 3 weeks post infection in vivo (115).  As mentioned, in vivo 
use of Ad-5 results in significant tropism to the liver and therefore represents an 
obstacle to targeting extrahepatic tissues (109). 
Despite the significant liver tropism of Ad-5, few studies have characterized the 
effect of adenovirus infection on hepatocyte function aside from adenovirus-induced 
hepatotoxicity.  A recent report demonstrated that disruption of lipid metabolism plays a 
role in liver pathology following liver infection by hepatitis C virus (HCV) (98).  Other 
studies allude to a correlation between adenoviral infection and aberrant lipid 
metabolism in other tissues.  Several serotypes of adenovirus have been shown to 
increase adipocyte differentiation and triglyceride accumulation in adipocytes (116).  
Rats infected with adenovirus-36 (Ad-36) showed an increase the expression of 
adipocyte acetyl CoA-carboxylase (ACC) and fatty acid synthase (FAS) (117) in 
adipose  tissue while Ad-5 infection has been linked to increased adiposity in mice 
(118).  There are 51 identified serotypes of adenoviruses.  Of those, Ad-5 has been 
exploited in its replication-deficient form as an in vivo and in vitro expression vector.  
Additionally, Ad-5 is currently a candidate gene-therapy vector for several clinical trials 
(119).  Based on the aforementioned studies, the potential for adenovirus tropism to the 
liver, and the use of adenoviruses to study hepatocyte function and potentially treat liver 
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disorders, studies were designed to test investigate the potential for Ad-5 to influence 
lipid metabolism via SREBP.   
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Review of the Group VIA calcium-independent phospholipase A2: 
 
 
I. Glycerophospholipids and Phospholipases 
Glycerophospholipids (GPL) are major components of cell membranes. Until the mid 
1980’s their function in cell biology was thought to be limited to a “bricks and mortar” 
role as constituents of cell membranes. However, the pioneering work of Irvine, 
Nishizuka, Berridge, and others (120-122) demonstrated that GPL have information 
content that is unleashed when these molecules are metabolized by phospholipases, a 
family of enzymes that hydrolyze ester bonds in GPL. The phospholipases A2 (PLA2) 
are defined as acylhydrolases that add water across the sn-2 ester bond, generating 
lysophospholipid and unesterified fatty acid products, both of which have the potential 
to be metabolized into biologically active signaling molecules. Although some members 
of this family also hydrolyze lysophospholipid (generating glycerophosphocholine and 
unesterified fatty acid products), the enzymes are classified together based on the 
phospholipase reaction.  
 
PLA2 enzymes have been categorized into 15 groups based on sequence homology and 
catalytic mechanism (123). Although the group classification scheme has been 
extremely useful for investigators in the PLA2 field, a streamlined and more simplified 
categorization has gained popularity among researchers in general. In this scheme, 
PLA2 enzymes are classified into four categories: secreted PLA2 (sPLA2), cytosolic 
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calcium dependent PLA2 (cPLA2), platelet-activating factor acetylhydrolase (PAFAH), 
and cytosolic calcium independent PLA2 (iPLA2). The sPLA2s are relatively small (14-
18 kDa) enzymes with rigid tertiary structures largely dictated by 5-7 disulfide bonds. 
These enzymes are strictly dependent on calcium which is involved in their catalytic 
mechanisms. Given the calcium requirement of sPLA2s (millimolar range) and the 
requirement for disulfide bonds in their tertiary structures, it has long been proposed 
that these are secreted enzymes that hydrolyze substrate in the extracellular space (124). 
However, a recent study shows that sPLA2 activity in gastric mucosal cells is not 
suppressed by a membrane impermeant inhibitor suggesting that the enzyme is active in 
an intracellular compartment (125). The cPLA2s are a broad class of enzymes which 
display both phospholipase and lysophospholipase activity (126). The best studied of 
these enzymes, cPLA2α (also known as the group IVA PLA2), exhibits the unique 
property of selective hydrolysis of arachidonyl GPL making it a key player in 
arachidonic acid (AA) mobilization and eicosanoid production (123;126). In addition, 
some members of the cPLA2 family translocate to membranes in response to increases 
in cytosolic calcium. This effect is mediated through the C2 domain, a motif that directs 
calcium-dependent binding to membrane GPL. PAFAH enzymes are distinguished from 
the other PLA2s by their substrate specificity which is focused on GPL containing 
relatively short native sn-2 acyl chains or oxidatively fragmented fatty acids such as 
those in oxidized low density lipoprotein (LDL) and damaged cell membranes (127). 
Both intracellular and secreted PAFAH isoforms have been identified. Importantly, the 
secreted group VIIA enzyme associates with lipoproteins and is the lipoprotein 
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associated PLA2 (LpPLA2) that has been connected with atherosclerosis and other 
vascular diseases (128;129). 
 
The iPLA2s are among the most recently described and least well-characterized of the 
PLA2s. These enzymes have the unique property that they are active in the absence of 
calcium, as this divalent cation is neither required for catalytic activity nor for 
translocation to membrane. Indeed, some studies suggest that iPLA2 activity is induced 
upon calcium depletion (130), suggesting that intracellular calcium may negatively 
regulate iPLA2 enzymes (see below). Interestingly, several recent studies suggest 
essential roles for iPLA2 in the regulation of store operated calcium channels (131). 
Like cPLA2, these enzymes exhibit significant homology to patatin, a lipase from potato  
(126). Homology searches have identified iPLA2 enzymes in a variety of species 
ranging from Pseudomonas aeruginosa bacteria which express ExoU, a phospholipase 
virulence factor that is cytotoxic to mammalian host cells (132) to Arabidopsis in which 
AtPLAI regulates basal jasmonic acid synthesis and is involved in resistance to fungal 
infection (133), to the potato enzyme patatin, to  human where iPLA2 has been 
implicated in ischemia-reperfusion injury following myocardial infarction (134;135), 
insulin sensitivity (136;137), and other biomedically relevant conditions (see below). 
Until recently, it was thought that the family of iPLA2 enzymes was derived from only 
two genes which encoded the group VIA (also known as iPLA2β) and group VIB 
(iPLA2γ) enzymes. However, recent sequence homology searches have identified 
additional members of the family (group VIC, group VID, group VIE, and group VIF 
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enzymes) that have the signature nucleotide binding motif (GxGxxG) and lipase 
consensus sequence (GxSxG) (138;139). iPLA2β exhibits broad tissue distribution, is 
constitutively expressed, and has important roles in basal GPL metabolism (123;140). 
In contrast, although iPLA2γ is expressed in a variety of tissues, especially high 
expression has been observed in heart and kidney (141-143).   As mentioned above, 
iPLA2 is involved in pathogenesis of several medically relevant disorders. Hence, the 
iPLA2s may be important targets for drug development. The group VIC, VID, VIE, and 
VIF enzymes have only recently been described and relatively little is known about 
them.  
 
II. iPLA2 Structure 
The iPLA2 enzymes are classified in group VI based on conserved structural 
characteristics including a C-terminal lipase consensus motif (GXSXG). The active site 
serine is the nucleophile that attacks the sn-2 carbonyl, generating an acyl-enzyme 
intermediate. iPLA2 enzymes also exhibit lysophospholipase and transacylase activity 
(144) and a recent report indicates that iPLA2β also hydrolyzes long chain acyl-CoA, 
indicating it has thioesterase activity as well (145). The group VI D, E, and F enzymes 
are triacylglycerol lipases and acylglycerol transacylases in addition to PLA2 activity 
(138). All of these activities are suppressed by bromoenol lactone (BEL), a suicide 
inhibitor of iPLA2 (146). This observation suggests that all of the activities are mediated 
by the same active site. In addition, several members of the family contain additional 
structural features that impinge on their subcellular localization and function. Prominent 
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among these is a series of 7-8 ankyrin repeats at the N-terminus of the group VIA 
(iPLA2β) enzymes (Figure 2).  Ankyrin repeats are involved in protein-protein 
interactions (147) and these motifs are believed to mediate oligomerization of iPLA2β 
into active tetramers (148;149) (Figure 3). Although iPLA2β also contains a putative 
bipartite nuclear localization sequence (123;140), only a few studies have localized it to 
the nucleus (150). Most evidence suggests that iPLA2β is likely in the endoplasmic 
reticulum and therefore associated with perinuclear compartments (123;151;152). Both 
group VIA (iPLA2β) and group VIB (iPLA2γ) PLA2s also contain a consensus 
nucleotide binding motif (GxGxxG) which exhibits homology to those of protein 
kinases (141;153). This feature is important, given the well-established regulation of the 
enzymes by ATP (154-156) (and see below). The C-terminus of iPLA2β contains a 
calmodulin binding motif (AWSEMVGIQYFR in hamster iPLA2) that is implicated in 
the regulation of iPLA2 activity through its association with calmodulin (157) as will be 
explained further below.  The group VIB enzyme (iPLA2γ) is distinguished by its C-
terminal  SKL peroxisome localization sequence (141). iPLA2γ also contains a N-
terminal mitochondrial targeting sequence and exhibits dual subcellular localization to 
the two compartments (158;159). Recent reports suggest that the mitochondrial 
localization of iPLA2γ has important implications for mitochondrial function and 
bioenergetic efficiency (143;159). Although iPLA2γ has also been observed in rat liver 
peroxisomes (160), the functional consequence of this localization remains somewhat 
obscure. As rat liver peroxisomes contain large amounts of arachidonyl GPL, it has 
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been suggested that this pool of enzyme is involved in AA release and eicosanoid 
production (160).   
  23  
Figure 2: Depiction of structure of (A) Group VIA PLA2 (iPLA2β) and (B)  Group 
VIB PLA2 (iPLA2γ). The active site serine is highlighted. 
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Figure 3: Regulation of iPLA2β Activity by Oligomerization. Active iPLA2β is 
proposed to be a homotetramer, formed through protein-protein interactions between 
the ankyrin repeat domains of iPLA2β monomers. Splice variants of the iPLA2β pre-
mRNA encode truncated proteins that retain the ankyrin repeat domain but lack the 
active site and C-terminus. These proteins interact with full length iPLA2β monomers 
and prevent oligomerization into active tetramers. 
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III. Alternative Splicing and iPLA2 isoforms 
The group VIA PLA2 (iPLA2β) gene undergoes a variety of alternative splicing events, 
generating variants that differ in their subcellular localization, catalytic activity, and 
likely cellular function (148;149;161). Two of the splice variants, group VIA-1 and 
group VIA-2 are known to encode functional PLA2 enzymes that differ in the number of 
ankryrin repeats (8 in group VIA-1, 7 in group VIA-2). The group VIA-2 isoform has 
only 7 ankyrin repeats due to a 54 amino acid insertion in the eight ankyrin repeat. This 
isoform results from an alternatively spliced exon (exon 8). The group VIA-2 isoform is 
slightly larger than group VIA-1 iPLA2 (752 amino acids versus 806 amino acids; 83 
kDa versus 88 kDa) and is proposed to be membrane-associated based on hydropathy 
plots (148;162). Another splice variant that encodes the group VIA-3 protein arises due 
to a 158 nucleotide insertion derived from an alternatively spliced exon that generates a 
premature stop codon. This protein contains the ankryin repeats, nucleotide binding 
motif and consensus lipase consensus sequence but does not include the C-terminal 
amino acids. The function of this ~70 kDa protein remains elusive. Two additional 
splice variants also encode premature stop codons due to alternatively spliced exon 10a. 
These insertions result in premature stop codons that terminate the proteins after the 
ankyrin repeat domain but before the active site. As such, group VIA ankyrin-1 and 
group VIA ankyrin-2 proteins are catalytically inactive. However, because these 
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proteins contain the ankryin repeat domain, they retain the ability to oligomerize with 
full length monomers (149;161). This property has important implications for the 
regulation of iPLA2β activity as will be examined below.  
 
There are two major isoforms of group VIB PLA2 (iPLA2γ) which arise from different 
start codons and result in proteins of ~77 and ~63 kDa (141). When over expressed in 
the myocardium, the enzyme is subject to a multitude of posttranslational modifications, 
as indicated by the large variety of isoforms observed in 2 dimensional gel analyses 
(159).  The iPLA2γ gene is also subject to alternative splicing (141;158). At present, it is 
not certain if the various isoforms of iPLA2γ differ in their relative catalytic efficiencies 
or substrate specificities, or other characteristics but a recent report indicates that they 
may have different subcellular localization (158). 
 
IV. Regulation of iPLA2 Activity 
Although early studies suggested that iPLA2 activity was not regulated by “classic” 
mediators of signal transduction (cytosolic calcium, phosphorylation), more recent 
studies have identified these and other factors as important modulators of iPLA2 
activity. One published purification protocol for iPLA2 includes a calmodulin affinity 
column (163). The Gross laboratory mapped the site of calmodulin binding to a peptide 
(AWSEMVGIQYFR) within 15 kDa of the C-terminus of iPLA2β and showed that this 
interaction suppresses catalytic activity (157;164).   As calmodulin interacts with client 
proteins in a calcium-dependent manner, these data are consistent with the observation 
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that iPLA2 activity increases in calcium-depleted cells (130;131;165). As discussed 
below, the negative regulation of iPLA2β by Ca2+/ calmodulin complexes has important 
implications for activation of store operated calcium channels (SOC) (131). In contrast, 
iPLA2 activity is induced when the enzyme binds Ca2+/ calmodulin dependent protein 
kinase βII in pancreatic β cells (166). This interaction is calmodulin-independent and 
results in activation of both enzymes.  
 
The original purification protocols for iPLA2 included ATP affinity columns (154;167), 
indicating that the enzyme binds ATP. For many years, it has been accepted that ATP is 
required for optimal iPLA2 activity (154-156). However recent studies indicate that 
ATP activates group VIA-2 iPLA2 but not the group VIA-1 protein (162). This 
observation is of particular interest because the 54 amino acid insertion that 
distinguishes these two isoforms does not disrupt the putative nucleotide binding site 
(G/AxGxxG). However, the insertion is highly enriched in proline residues 
(PX5PX8HHPX12NX4Q) making it likely that conformational changes in this part of the 
protein modulate ATP binding to the adjacent nucleotide binding site. Although the 
nucleotide binding site is highly homologous to those of protein kinases (153), ATP 
binding to this site has not been confirmed experimentally. Our preliminary experiments 
indicate that a mutant iPLA2β protein lacking a glycine in the putative nucleotide 
binding site exhibits reduced binding to ATP agarose and minimal catalytic activity 
(Figure 4). Non-hydrolyzable analogs of ATP and other nucleotide triphosphates can 
substitute for ATP, suggesting that this effect is not mediated through phosphorylation 
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of the enzyme (154-156). ATP protects iPLA2 from thermal denaturation, an indication 
that it stabilizes iPLA2 proteins and/ or oligomers (144;155;156). However, the detailed 
molecular mechanism of iPLA2 activation by ATP remains elusive at present. 
 
As noted above, iPLA2 activity is induced by non-hydrolyzable analogs of ATP 
(154;155;155) suggesting that this effect is not mediated through phosphorylation of the 
enzyme. However, several investigators have proposed that iPLA2 is activated 
downstream of serine-threonine protein kinases, PKC and p38 in particular (151;168-
171). Direct evidence that active iPLA2 is a phosphoprotein remains elusive. To date, 
only one study has demonstrated stimulus-dependent phosphorylation of iPLA2β in 
response to activation through FcγRI (172). 
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Figure 4: iPLA2β ATP Binding Mutant has minimal catalytic activity. (A) HEK 293 
cells were transiently transfected with vector encoding wild type iPLA2β (wt) or mutant 
iPLA2β (mt) in which G433 was replaced with aspartate.  Whole cell homogenates were 
prepared and incubated with ATP agarose.  The unbound fraction and the ATP agarose 
eluent (bound fraction) of each preparation were subjected to SDS-PAGE followed by 
immunoblot analysis for iPLA2β. (B) iPLA2 activity was quantified in whole cell 
homogenates of HEK cells transiently transfected with wild type iPLA2β or mutant 
iPLA2β. The data shown are compiled from four independent experiments.  iPLA2 
activity (expressed as pmol substrate hydrolyzed/ min/ mg cell protein) was lower in 
homogenates expressing mutant iPLA2β (p < 0.0001).    
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Figure 4 
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Radiation inactivation studies indicate that active iPLA2β is a homotetramer (154). This 
observation indicates oligomerization as another mechanism for the regulation of iPLA2 
activity. The N-terminal half of iPLA2β protein is largely composed of a series of 
ankryin repeats (163;173), a motif known to be involved in protein-protein interactions 
and that is likely to mediate oligomerization of iPLA2 monomers. Several recent studies 
suggest that the group VIA ankyrin-1 and group VIA ankyrin-2 proteins encoded by 
alternatively spliced iPLA2β mRNAs (148;149;161) are endogenous dominant negative 
proteins that suppress iPLA2β activity (Figure 3). These proteins contain the N-terminal 
ankryin repeats but lack the C-terminal active site. As such, ankryin iPLA2 proteins 
retain the ability to associate with full length iPLA2β. Importantly, group VIA ankryin-1 
coimmunoprecipitates with full length iPLA2β and suppresses catalytic activity when 
the two proteins are co-expressed (148;149;161). Together these observations support 
the hypothesis that group VIA ankryin-1 is an endogenous dominant negative inhibitor 
of iPLA2β, a characteristic that may be important for cell cycle-dependent regulation of 
the enzyme as will be explained below. 
 
 
V. Regulation of iPLA2 Expression 
Although iPLA2 was once thought to be a constitutively expressed enzyme, strictly 
involved in basal GPL metabolism, a growing body of evidence suggests that its 
expression is regulated in response to a variety of stimuli. Several recent studies 
indicate that iPLA2β expression is induced in retina, both during phagocytosis of 
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photoreceptor outer segments and in endothelial cells stimulated to proliferate upon 
interaction with retinal pericytes (174;175). iPLA2β is expressed in the cerebral cortex 
and hippocampus and its expression declines during aging (176). Expression of the 
enzyme is also down regulated in myocardial tissues of rats undergoing congestive heart 
failure (177). Several recent studies indicate that iPLA2 expression is regulated by lipids 
and in tissues involved in systemic lipid metabolism. Enzyme expression and 
transcriptional activity of the iPLA2β promoter are induced lipid depleted Chinese 
hamster ovary (CHO) cells cultured in lipoprotein-depleted serum (LpDS) (49). Both 
iPLA2β and iPL:A2γ expression increases during adipocyte differentiation, a response 
that likely has important functional consequences for adipocyte development (178). 
Relatively little is known about the molecular mechanisms that regulate iPLA2 
expression. The 5’ flanking region of the human iPLA2β gene contains a sterol response 
element (SRE). Sterol response element binding protein-2 (SREBP2) has been shown to 
bind this element and is likely the mechanism for iPLA2 induction in lipid-depleted 
cells (49). The iPLA2γ gene contains a proximal E-box that interacts with MyoD, 
thereby augmenting transcription of the gene (158). Given the mounting evidence for 
iPLA2 involvement in a variety of biomedically relevant conditions, a more detailed 
understanding of the mechanisms regulating iPLA2 expression is warranted and is 
almost certain to be an active area of research in the future. 
 
VI. Biological Functions of iPLA2
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Most studies of the biological functions of iPLA2 have focused on iPLA2β. However in 
recent years there has been increased interest in the functions of iPLA2γ. (141;179). The 
observation that the R enantiomer of BEL (R-BEL) inhibits predominantly iPLA2γ, 
whereas S-BEL selectively inhibits iPLA2β (180), has provided researchers with a 
pharmacological means to distinguish between the activities of the two major forms of 
iPLA2.  The remainder of the attention of this section will distinguish between iPLA2β 
and iPLA2γ when possible.  However, it must be noted that many studies have used 
racemic BEL to study iPLA2 function and/ or were conducted before gene silencing 
tools were available. Such studies therefore cannot distinguish between the two forms 
of the enzyme, though it is generally assumed that the majority of them are focused on 
iPLA2β.   
 
A. Glycerophospholipid (GPL) Metabolism 
1. Acyl chain remodeling 
For many years, iPLA2 has been proposed as a major regulator of basal GPL 
metabolism. Among the roles proposed for iPLA2 in this regard is regulation of the acyl 
chain composition of GPL. In mammalian cells, long chain polyunsaturated fatty acids 
(PUFA) are typically esterified to the sn-2 carbon and are incorporated into GPL 
through a remodeling process (41;181-183). The proposed mechanism for this process 
is GPL hydrolysis by a PLA2, generating a lysophospholipid acceptor for PUFA. Once 
incorporated into GPL (typically phosphatidycholine (PC) initially), PUFA are 
remodeled into other GPL classes (primarily phosphatidylethanolamine, PE). This 
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process is especially important in inflammatory cells (macrophages, neutrophils, for 
example) that are highly enriched in arachidonyl GPL and are sources of AA for 
eicosanoid production (40;41). Balsinde et al (184;185) were among the first to 
demonstrate a role for iPLA2β in remodeling, as this process was inhibited in P388D1 
mouse macrophages by bromoenol lactone (selective iPLA2 inhibitor) and an antisense 
oligonucleotide targeting iPLA2β. Similar results have been reported in uterine stromal 
cells (186). In both uterine stromal cells and P388D1 macrophages, iPLA2 inhibition is 
associated with an acute reduction in the lysophospholipid acceptors required for AA 
remodeling. Conversely, over expression of iPLA2β or iPLA2γ results in accumulation 
of select species of lysophosphatidylcholine (LPC) (159;187).  Together, these data 
suggest that iPLA2 may control the incorporation of AA into GPL, thereby making the 
enzyme an attractive candidate for drugs to control eicosanoid production.  In addition, 
a recent study indicates that iPLA2γ is involved in the acyl chain remodeling that 
generates the tetra C18:2 species of cardiolipin that is essential for Complex IV function 
and mitochondrial respiration (143).  However, it must be noted that studies in variety 
of cells and tissues, including pancreatic islet cells, an insulinoma cell line, T cells, and 
most recently in macrophages of iPLA2β-null mice suggest that the acyl chain 
composition of GPL does not change when iPLA2β expression or iPLA2 activity are 
modulated (136;188-191). Together, these studies suggest that iPLA2 likely regulates 
acyl chain remodeling in a select subset of cells and tissues.  
 
2. Regulation of GPL Mass 
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The other major role of iPLA2 in basal GPL metabolism is related to the regulation of 
phosphatidylcholine (PC) mass (PC homoestasis). This function is essential for cell 
biology not only because PC is a reservoir for important bioactive lipids and signaling 
molecules, but also because PC is the most abundant GPL in mammalian cells and 
therefore has a vital role in membrane integrity. An early study by Walkey et al (192) 
demonstrated that over expression of the rate limiting enzyme in PC synthesis (CTP: 
phosphocholine cytidylyltransferase, CCT) resulted in only modest increases in PC 
mass due to increased turnover of this GPL in HeLa cells. Subsequently, several groups 
showed that this turnover was associated with an accumulation of 
glycerophosphocholine (GPC, the product of PLA2 followed by lysophospholipase 
activity) and that this was blocked when cells were treated with bromoenol lactone 
(193;194). Importantly, iPLA2 activity and expression were elevated in response to 
CCT over expression (193). Together, these observations suggest that PC mass is 
maintained through a dynamic balance between CCT and iPLA2 activities. More recent 
studies suggest that iPLA2β also regulates accumulation of PC mass for daughter cell 
membranes (161), an observation that is especially interesting given recent studies 
linking iPLA2β to cell cycle progression and cell proliferation (195-198). This topic will 
be treated below and suggests iPLA2 as a potential target for chemotherapeutic drugs. 
 
3. Arachidonic acid metabolism and eicosanoid production 
Like other long chain polyunsaturated fatty acids, arachidonic acid (AA) is primarily 
esterified in the sn-2 position of mammalian GPL. Upon its release from GPL by 
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phospholipase A2, AA can be shuttled to the cyclooxygenase (COX) and lipoxygenase 
pathways for eicosanoid synthesis ((37).  It is well-established that cPLA2 and sPLA2 
are responsible for AA release and subsequent eicosanoid production in response to a 
variety of stimuli and in many cell types (199-201).  This is likely related to the 
substrate specificity of cPLA2, which preferentially targets arachidonate-containing 
GPL (202;203). However, evidence has accumulated that iPLA2 can participate in AA 
release and eicosanoid production under certain conditions.  For example, HEK293 
cells cotransfected with iPLA2 and COX-1 exhibit AA release and prostaglandin E2 
(PGE2) production when stimulated with calcium ionophore A23187 but not in response 
to IL1β (204). In phagocytes, AA release in response to oxidative stress has been shown 
to rely on iPLA2 activity (205;206) and leukotriene B4 (LTB4) production by zymosan-
stimulated granulocytes is attenuated by the iPLA2 inhibitor BEL (207).  iPLA2 is also 
involved in eicosanoid synthesis in mesanglial cells, as BEL partially blocks AA release 
and subsequent prostaglandin E2 (PGE2) production by rat mesanglial cells stimulated 
with interleukin-1β (IL-1β) and dibutyryl cAMP (208).  Although iPLA2 is involved in 
zymosan-stimulated AA release in P388D1 cells, (171;209), PAF-induced AA release is 
iPLA2-independent in the same cell line (210). Similarly, iPLA2 is not involved in PAF-
stimulated AA release in U937 cells, but these cells exhibit iPLA2-dependent AA 
release in response to activation through FcγRI (172).   Together, these observations 
indicate that cell type and stimulus dictate whether iPLA2 is involved in AA release and 
eicosanoid production. AA is also metabolized by the CYP epoxygenase and CYP 
hydroxygenase pathways to generate the eicosanoids epoxyeicosatrienoic acid (EET) 
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and hydroxyeicosatetraenoic acid (20-HETE), respectively (211).  A recent study 
indicates that iPLA2-generated AA may be metabolized by these pathways, resulting in 
EET production that in turn induces calcium influx (212).  Taken together, these studies 
indicate that sPLA2 and cPLA2 are not the only mediators of AA release. Hence, iPLA2 
should be considered as a potential target for anti-inflammatory drugs designed to block 
eicosanoid production  
 
B. Pathogenesis and Innate Immune Response 
1. Innate Immune response  
Recent studies suggest several important roles for iPLA2 in the host immune response. 
In plants, an iPLA2 homolog (AtPLA1 in Arabidopsis) is associated with basal 
production of jasmonic acid and resistance to infection by the fungus Botrytis cinerea 
(133). iPLA2 homologs in tobacco (NtPat) have also been associated with jasmonic acid 
production in response to fungal infection (213).  iPLA2 is also important for the innate 
immune response in humans and other mammals. In addition to its established role in 
AA release and eicosanoid production (171;205;206), iPLA2 is involved in a variety of 
additional functions associated with macrophage biology. iPLA2-derived AA is required 
for adherence and spreading of primary mouse macrophages (214).  Lysoszyme 
secretion by U937 human monocytes is dependent on iPLA2-derived 
lysophosphatidylcholine (LPC) and suppressed by BEL and antisense oligonucleotides 
targeted to iPLA2β (215). LPC is also essential for clearance of apoptotic cells, as iPLA2 
inhibitors suppress both macrophage chemotaxis to and phagocytosis of apoptotic cells 
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(216;217).  In contrast although BEL also inhibits phagocytosis of red blood cells 
opsonized with IgG, AA restores this activity, suggesting that it is mediated by the fatty 
acid product of iPLA2 not the lysophospholipid (218). iPLA2 is also involved in 
recognition of apoptotic cells, as iPLA2-derived LPC in the outer leaflet of the plasma 
membrane is an epitope recognized by IgM antibodies (219). Bromoenol lactone and 
iPLA2 antisense oligonucleotides attenuate macrophage chemotaxis in response to 
monocyte chemoattractant protein-1 (MCP-1) (220). Infection with 
encephalomycarditis virus (EMCV) stimulates expression of inducible nitric oxide 
synthase (iNOS) in mouse macrophages. Experiments with the R- and S- enantiomers of 
BEL indicate that this induction occurs downstream of iPLA2β-mediated activation of 
cyclic AMP response element binding protein (CREB) (221). This observation is 
consistent with other reports that double-stranded RNAs induce phosphorylation of 
CREB in an iPLA2-dependent manner (222;223).  Other lines of study suggest that 
iPLA2 plays an essential role in protecting host cells against the innate immune 
response. For instance, overexpression of iPLA2γ and β in glomerular epithelial cells 
reduces cellular damage and proteinuria induced upon complement activation (224).  
Taken together, these studies indicate that iPLA2 plays essential roles in macrophage 
biology and the innate immune response. This is an important consideration in the 
design and implementation of drugs targeting iPLA2 activity as such compounds are 
likely to be immunosuppressive if administered systemically or for extended periods of 
time. 
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2. Pathogenesis of Pseudomonas aeruginosa 
As noted above mammalian iPLA2 is highly homologous to ExoU, a phospholipase A2 
and virulence factor expressed by Pseudomonas aeruginosa that is directly exported 
into the cytosol of mammalian host cells through a type III secretion system (132;225). 
ExoU shares a variety of characteristics with iPLA2 including hydrolysis of zwitterionic 
GPL in vitro, induction of AA release when injected into the cytosol of CHO cells, 
calcium-independent activity, lysophospholipase activity, and an active site serine 
(226;227) (227;228) (229). However, although ExoU activity is suppressed by methyl 
arachidonyl fluorophosphonate (MAFP), an inhibitor of iPLA2 and cPLA2, BEL (a 
selective inhibitor of iPLA2) only partially suppresses ExoU activity (227;228). These 
data indicate that the ExoU PLA2 is similar but not identical to mammalian iPLA2. 
Importantly, a variety of studies indicate that ExoU is an essential virulence factor for 
P. aeruginosa (225) (230) (227) (231) (232). These observations suggest that selective 
pharmacological inhibitors of the phospholipase activity of ExoU may be effective 
treatments for P. aeruginosa infection.   
 
C. Calcium Signaling and Homeostasis 
Another emerging role for iPLA2 relates to calcium homeostasis, specifically the 
replenishment of depleted intracellular calcium stores. The mechanism of this 
replenishment has been hotly debated for many years, with two major models emerging: 
the “conformational coupling” model in which IP3 receptors/ calcium channels in the 
ER membrane become physically associated with calcium channels in the plasma 
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membrane and the “calcium influx factor” (CIF) model which postulates that a 
diffusible molecule generated upon depletion of calcium stores interacts with store 
operated channels (SOC) in the plasma membrane and induces calcium influx 
(233;234). Strong evidence of a role for iPLA2 in the CIF model has emerged from 
recent studies by the Bolotina group and others. These studies were prompted by the 
observation that iPLA2 activity is induced upon calcium depletion and that the enzyme 
associates with calmodulin (157;164). Based on these observations, Smani et al treated 
smooth muscle cells (SMC) with thapsigargin (TSG) to deplete ER calcium stores and 
demonstrated an induction of iPLA2 activity (235). iPLA2 activity is also activated by 
partially purified CIF and this is at least in part mediated through dissociation of 
calmodulin, a negative regulator of the enzyme (131). Importantly, calcium influx 
through calcium release-activated channels (CRAC) is blunted when SMC or rat 
basophilic leukemia (RBL) cells are pretreated with the S- enantiomer of BEL (selective 
iPLA2β inhibitor) or antisense oligonucleotides targeting iPLA2β (131;236). Similar 
results have been observed in platelets, prostate cancer cells, cerebellar astrocytes, and 
Jurkat T cells, suggesting that iPLA2-dependent replenishment of calcium stores is a 
commonly used mechanism for restoring calcium homeostasis in a variety of cells and 
tissues (131;236-238). The lysophospholipid product of the iPLA2 reaction is essential 
for this process, as LPC restores activation of SOC in BEL-treated cells (131;237). 
Based on these observations, Bolotina has proposed a model wherein CIF (still a poorly 
defined entity) promotes dissociation of iPLA2 from calmodulin thereby activating the 
enzyme and prompting generation of LPC that then activates SOC and allows calcium 
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influx to replenish intracellular stores (233;234). Recent studies suggest that iPLA2 may 
regulate calcium influx through transient receptor potential (TRP) channels as well 
(239), indicating the potential for a wider role of the enzyme in calcium homeostasis. 
There are a variety of potential applications for pharmacological interventions to 
regulate iPLA2-dependent activation of SOC. Most notably, such strategies could be 
useful in treatment of Duchenne muscular dystrophy which is characterized by 
progressive muscle destruction secondary to uncontrolled calcium entry through SOC. 
Boittin et al have recently shown that iPLA2 expression is 2-3 fold higher in dystrophic 
than normal skeletal muscle fibers and that BEL restores calcium entry to normal levels 
in these tissues (240). Increased cytosolic calcium is required for exocytosis of mast cell 
granules, making iPLA2 an attractive target for controlling this process and thereby the 
contribution of mast cells to type I hypersensitivity (allergy). As replenishment of 
intracellular calcium stores is essential for homeostasis and given the diverse array of 
cells and tissues that mediate this process in an iPLA2-dependent manner, any drugs 
designed to suppress iPLA2 activity will require exquisite tissue selectivity to avoid 
global disruption of calcium homeostasis. 
 
D. Cell Proliferation, Survival, and Apoptosis 
1. iPLA2 and apoptosis 
Several lines of evidence have implicated free AA in apoptosis (241-243) and in doing 
so have prompted investigation into the relationship between iPLA2 and apoptosis. 
Indeed, there are now numerous studies linking iPLA2 to apoptosis secondary to 
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chemotherapeutic drugs, ER stress, and other agents. For example, iPLA2 inhibition 
protects renal cells from apoptosis induced by the chemotherapeutics cisplatin and 
vincristine presumably through the retention of AA in GPL (244). A similar study in 
rabbit renal proximal tubule cells demonstrated that iPLA2γ works together with 
caspase 3 and p53 to facilitate cisplatin-induced apoptosis (151). Kinsey et al have 
recently extended this study and observed that iPLA2γ-generated AA plays a central 
role in mediating the mitochondrial permeability transition that leads to cell death (245).  
Studies in U937 monoblastic leukemia cells indicate that iPLA2 is involved in apoptosis 
induced by TNFα and anti-Fas antibodies as iPLA2 inhibitors suppress both AA release 
and apoptosis induced by these agents (246;247). Caspase 3 cleaves iPLA2β at Asp183 to 
produce a truncated enzyme with enhanced enzymatic activity that is likely responsible 
for AA release during apoptosis as well as the migration of non-apoptotic ovarian 
cancer cells (247;248). Polycyclic aromatic hydrocarbons in cigarette smoke induce AA 
release from and apoptosis of endothelial cells in an iPLA2-dependent manner (249). 
While some studies have connected iPLA2β to apoptosis secondary to oxidative stress 
(250), others suggest that this mechanism of cell death, while iPLA2-dependent, is not 
mediated through apoptosis (150). Whether apoptotic or non-apoptotic, cell death in 
response to oxidative stress may be controlled by feedback mechanisms that result in 
covalent modifications of iPLA2β that suppress its catalytic activity (251). Several 
recent studies connect iPLA2 to apoptosis secondary to ER stress induced by free 
cholesterol loading, calcium depletion and other mechanisms.  However, it is not yet 
clear whether these responses are mediated by iPLA2β,  iPLA2γ, or both (151;191;252). 
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Together, these studies suggest iPLA2 is a key player in programmed cell death of a 
variety of cells and tissues and in response to a variety of stimuli.  
 
The mechanism by which iPLA2 augments apoptosis is still under investigation, but is 
likely cell type- and/ or stimulus-specific. iPLA2-dependent apoptosis may be secondary 
to changes in lipid metabolism and mass in apoptotic cells. As noted above, some 
studies suggest that apoptosis is induced due to AA accumulation, a likely outcome of 
iPLA2 activity (241-243;253). There is evidence that iPLA2 is involved in acyl chain 
remodeling and that apoptosis ensues when this process is inhibited (188;253).  
However, as the role for iPLA2 in acyl chain remodeling appears to be limited to 
macrophage cell lines (136;188;190;191), this is likely not a major mechanism for 
iPLA2-mediated apoptosis. Other studies suggest that apoptosis downstream of AA 
accumulation is mediated through the generation of ceramide (15), a proapoptic 
sphingolipid derived from sphingomyelin hydrolysis (254). Much of this work stems 
from an early report that AA and other fatty acids mediate tumor necrosis factorα- 
(TNFα-) induced sphingomyelin hydrolysis in a PLA2-dependent manner (255).  In 
recent years, iPLA2β-dependent generation of ceramide has emerged as an important 
mechanism for apoptosis (252;256). One recent report demonstrates that iPLA2β 
increases ceramide through induction of neutral sphingomyelinase during ER-stress 
induced apoptosis in INS-1 insulinoma cells (252).  As expected, BEL (a selective 
iPLA2 inhibitor) blocks neutral sphingomyelinase activity, ceramide generation and 
apoptosis during ER stress in INS-1 cells.  Conversely, iPLA2β over expression 
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exacerbates ER-stress induced apoptosis.  BEL also attenuates apoptosis secondary to 
depletion of ER calcium stores whereas over expression of iPLA2β exacerbates this 
process (256).  In these studies, increased ceramide levels correlate with the 
accumuation of a 62-kDa iPLA2β protein resulting from caspase-3 cleavage.  This 
truncated iPLA2β has increased catalytic activity, reminiscent of the highly active, 
caspase-processed iPLA2β that is generated during Fas-mediated apoptosis of U937 
cells (246;247). 
 
It has also been suggested that iPLA2 is involved in the intrinsic apoptosis pathway that 
involves cytochrome c release from the mitochondria and subsequent caspase activation 
and apoptosis.  Both iPLA2β and iPLA2γ can associate with the mitochondria (158) 
(245;257-259).  iPLA2 accentuates mitochondrial permeability transition, thereby 
promoting cytochrome C release and the intrinsic pathway of apoptosis (260;261). The 
selective iPLA2γ inhibitor R-BEL suppresses calcium-induced swelling of rabbit renal 
cortex mitochondria, suggesting a role for iPLA2γ in this process. In contrast, iPLA2β is 
down-regulated during staurosporine-induced apoptosis and over expression of the 
enzyme protects CHO and INS-1 cells from loss of mitochondrial potential and 
cytochrome C release (257). Although the reason for these disparate responses is 
unclear at present, they provide further evidence that the role of iPLA2 in cell growth 
and death is likely to be cell type- and stimulus-specific. 
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Together, these studies suggest that iPLA2 is involved in the induction of apoptosis in 
many cells and tissues. Other studies suggest that iPLA2 also plays a vital role in 
clearance of apoptotic cells. iPLA2-derived lysophosphatidylcholine is recognized by 
IgM antibodies, resulting in complement activation, opsonization, and clearance of 
apoptotic cells (219).  There is also evidence that iPLA2 activity may facilitate the 
externalization of phosphatidylserine, another marker of apoptotic cells that promotes 
their clearance (219;247).  As noted above, caspase processed iPLA2 is highly active, 
generating both free fatty acid and lysophospholipid products (217;247;248). 
Lysophosphatidylcholine (LPC), in particular, is a chemoattractant for monocytes 
which recruits these cells and thereby promotes phagocytosis and clearance of apoptotic 
cells (217).  
 
In summary, there is considerable evidence that iPLA2 promotes not only apoptosis but 
also clearance of apoptotic cells by the innate immune system. These studies suggest 
that products of the iPLA2 reaction are potential drug targets, as these molecules or their 
mimetics might be useful as adjuvants together with standard approaches to 
chemotherapy. 
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 2. iPLA2 and cell survival, growth and proliferation 
Although iPLA2 has important roles in a variety of apoptotic responses 
(150;151;191;244;246-250;252), there is substantial evidence that the enzyme is 
required for proliferation as well.  Cell type, the nature of the cell environment, and the 
absence or presence cellular stressors may determine whether iPLA2 exerts 
antiapoptotic or proapoptotic pressure.  For instance, although iPLA2β contributes to 
apoptosis in ER-stressed INS-1 insulinoma cells (252), in the same cell line iPLA2β is 
also required for optimal proliferation and prevents mitochondrial cytochrome c release, 
loss of mitochondrial membrane potential and apoptosis in response to staurosporine  
(189;257).   BEL suppresses proliferation of mitogen-stimulated Jurkat T cells, 
endothelin-stimulated Schwann cells, and serum-activated fibroblasts (262-264).  
Importantly, ovarian cancer cell lines with attenuated iPLA2β expression exhibit 
reduced tumorigenicity in nude mice (198).  Both p53-dependent and independent 
mechanisms for iPLA2 suppression of proliferation have been demonstrated (195;198). 
Although most studies suggest that inhibition of iPLA2β by BEL or genetic knock down 
results in S phase arrest (195;197;262;264), there is also evidence that iPLA2β is 
required for progression through the G2/M transition in Jurkat T cells and ovarian 
cancer cells (198;263). 
 
The molecular connection between iPLA2 and cell cycle progression is unclear at 
present and likely to vary with different cell types and stimuli. As noted above, iPLA2 
activity is cell cycle-dependent and regulated in a manner consistent with the 
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accumulation of lipid for daughter cell membranes (161).  Arachidonic acid (AA) 
reverses the inhibition of HUVEC and Caco-2 cell proliferation by BEL (196;197).  The 
effects of AA on proliferation are likely related to effects of AA-derived eicosanoids on 
cancer progression (14;265).  Along these lines, over expression of iPLA2γ in human 
colorectal adenocarcinoma HCA-7 cells leads to increased AA and eicosanoid 
production resulting in increased proliferation (266).  Evidence also suggests that the 
lysophospholipid product of iPLA2 is involved in cell growth and cancer cell 
progression.  Lysophosphatidic acid (LPA) is a potent mitogen for many cell types and 
is readily exploited by transformed cells for proliferation and metastasis (267).  For 
example, LPA generated by human peritoneal mesothelial cells induces chemotaxis of 
SKOV-3 ovarian cancer cells (268).  In this system, BEL attenuates both the production 
of LPA and the chemotaxis of SKOV3 cells.  There is also evidence that ovarian cancer 
cells synthesize LPA in an iPLA2-dependent manner and that this lipid mediator acts in 
an autocrine fashion to induce proliferation and migration (198;269).  LPA releases 
BEL-treated ovarian cancer cells from S phase arrest as well (198).    
 
Together, these studies demonstrate that iPLA2 activity is associated with both 
programmed cell death and proliferation of cancer and normal cells. As discussed 
previously, the pro-proliferative or pro-apoptotic effects of iPLA2 are likely dependent 
on cell type and the nature of external stimuli. Thus, although iPLA2 is an attractive 
candidate for development of anti-cancer drugs, such strategies must be carefully 
designed to balance these two opposing effects of the enzyme. 
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E. iPLA2 in metabolism 
 
1. iPLA2 and glucose-stimulated insulin secretion 
Dysfunction of and insufficient glucose-stimulated insulin secretion from pancreatic 
islet β cells are pathological manifestations of diabetes mellitus.  Fatty acids are 
required for proper β cell function, as fatty acid deprivation of islet cells results in 
decreased insulin secretion in response to glucose (270).  Plasma, lipoproteins, 
intracellular triglyceride and GPL have all been proposed as the source of fatty acid for 
proper islet function (271). Glucose stimulates both insulin secretion and AA release 
(272-274) and inhibitors of GPL hydrolysis suppress insulin secretion  (275-281). These 
observations suggest PLA2 as a potential regulator of β cell function and there is 
accumulating evidence to indicate that this regulation is mediated by iPLA2. Early 
studies from the laboratories of Gross and Turk demonstrated that pancreatic islets 
contain a PLA2 that has the same properties as the enzyme that has come to be called 
iPLA2, including calcium-independence, inhibition by BEL, and activation/ stabilization 
ATP and its non-hydrolyzable analogs (282;283). Although the islet cell enzyme has 
been definitively identified as iPLA2β, a recent report indicates that this enzyme differs 
from other isoforms of iPLA2β in that it is 70 kDa  (versus “native” iPLA2β which is 
84-88 kDa) (137;284). The origin of the 70 kDa isoform of iPLA2β in islet cells is still 
in question, but it does not appear to be encoded by a splice variant of the iPLA2β pre-
mRNA (137). The signaling pathways stimulated by glucose provide additional 
  49  
evidence of a role for iPLA2 in glucose-stimulated insulin secretion.  Cyclic AMP 
(cAMP) signaling is required for glucose-stimulated insulin secretion from β cells 
(285;286). cAMP-elevating agents induce translocation of iPLA2β to a perinuclear 
compartment (286) (287) and it has been proposed that this allows the enzyme to access 
and release AA from GPL in the ER (288;289).  Like cAMP signaling, changes in 
intracellular calcium facilitate glucose-stimulated insulin secretion (290). PLA2 
products induce calcium release from ER stores in β cells (273) and BEL inhibits 
glucose-stimulated increases in intracellular calcium (276). The strongest evidence for 
involvement of iPLA2 in insulin secretion comes from studies in which islet cells are 
genetically manipulated or treated with BEL before stimulation with glucose. Over 
expression of iPLA2β in INS-1 insulinoma cells not only induces proliferation but also 
increases glucose-stimulated AA release (287;291).   Conversely, both BEL and siRNA/ 
shRNA targeted against iPLA2β suppress glucose-stimulated insulin secretion 
(189;291). Exogenous AA reverses effects of BEL, consistent with previous evidence 
for AA involvement in insulin secretion (7;291).  Studies in animal models provide 
additional support for a role for iPLA2β in pancreatic β cell function and highlight the 
ability of the enzyme to influence systemic glucose homeostasis.  Mice expressing an 
islet-specific iPLA2β transgene have lower fasting glucose and higher insulin levels 
than do wild type mice. These mice also perform better in glucose tolerance tests (187). 
In contrast, mice treated with BEL or shRNA targeted to iPLA2β demonstrate decreased 
in insulin secretion and impaired glucose tolerance (291). Furthermore, iPLA2β 
knockout mice exhibit insufficient insulin secretion in response to glucose and forskolin 
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when maintained on chow diet and develop severe glucose intolerance on a high-fat diet 
(136;187).  When treated with streptozotocin, iPLA2β knockout mice experience more 
severe hyperglycemia than do wild-type mice (136).  Collectively, these findings 
provide strong evidence of a role for iPLA2-derived bioactive lipids in glucose 
homeostasis and spotlight iPLA2 as a possible therapeutic target for the treatment of 
diabetes.   
 
2. iPLA2 and adipocyte/ hepatocyte biology 
Adipogenesis, the differentiation of preadipocytes into mature adipocytes, relies on the 
broad and concerted regulation of genes by PPARγ, CCAAT/enhancer binding protein 
(C/EBP)α and SREBP1, also referred to as adipocyte determination and differentiation-
dependent factor 1 (ADD-1) (292;293).  iPLA2β and iPLA2γ expression increases 
during adipocyte differention (178) and has been shown to play an essential role in 
adipogenesis.  Inhibition of iPLA2β and iPLA2γ with BEL enantiomers selective for 
either of the two proteins blocks differentiation of 3T3-L1 preadipocytes (178).  In 
addition, siRNA directed against either iPLA2 attenuates PPARγ and C/EBPα induction 
by a cocktail of adipogenic hormones.  Troglitazone, a PPARγ agonist, reverses effects 
of iPLA2 inhibition and restores adipogenesis.  Citing evidence that eicosanoids and 
lysophospholipids promote adipocyte differentiation (294-297) and that these molecules 
and unesterifed fatty acids can activate PPARγ (294;298-301), Su et al speculate that 
iPLA2 provides PPARγ agonists that drive differentiation (178).     
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Many of the genes encoding enzymes involved in fatty acid, triglyceride, and 
cholesterol synthesis contain sterol response elements (SRE) that allow for feedback 
regulation of expression (25;48;302).  SREs promote gene expression when they are 
bound by sterol regulatory element binding proteins (SREBPs), members of the basic-
helix-loop-helix family of transcription factors. The nuclear pool of SREBP1 is 
controlled at two levels: expression of precursor SREBP1 protein and processing to its 
mature, transcriptionally active form (25;48). In addition to the well-established role for 
sterols in regulation of SREBP, polyunsaturated fatty acids (PUFAs) also suppress 
SREBP processing and translocation (39;43;79). The effect of PUFAs appears to be 
largely specific for SREBP1 (76;80) and therefore effects of PUFAs are most apparent 
on fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and other lipogenic genes 
associated with triglyceride synthesis.  To date, all of the published studies have been 
performed in cells treated with exogenous PUFA or animals maintained on PUFA-rich 
diets. We hypothesize that iPLA2 is an endogenous source of PUFA capable of 
inhibiting SREBP. To test this hypothesis, we modulated iPLA2β expression and 
activity in Chinese hamster ovary (CHO) cells and HepG2 human hepatoma cell lines 
and then measured SREBP1 expression, functional activity, and expression of SREBP1 
target genes. As shown in (Figure 5), iPLA2 inhibition and over expression result in 
respective increases and decreases in transcriptional activity of expression of SREBP. 
These findings not only indicate a role for iPLA2 in hepatic lipid metabolism, but 
suggest a potential role for the enzyme in adipogenesis as PPARγ expression is 
transcriptionally controlled by SREBP in hepatocytes and adipocytes (303).   Thus, 
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iPLA2 has important roles in both hepatic and adipocyte biology. Given the relevance of 
these tissues to systemic lipid metabolism, iPLA2 is likely to be an important target for 
drugs that control obesity, fatty liver disease, and other manifestations of the metabolic 
syndrome. 
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Figure 5: iPLA2β Regulates Sterol Response Element Binding Protein (SREBP). 
Chinese hamster ovary (CHO) cells were transiently transfected with expression vector 
to over express iPLA2β (A) or siRNA to suppress endogenous iPLA2β (B). 
Subsequently, cells were transfected with luciferase reporter construct (pSynSRE) 
containing sterol response elements (SRE). Luciferase activity was quantified as a 
measure of functional SREBP protein in the cells. SREBP function was reduced in cell 
over expressing iPLA2β and augmented in cells with reduced iPLA2β expression (p < 
0.01). 
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Figure 5 
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3. iPLA2 in mitochondrial function and energy homeostasis 
Several recent reports from Mancuso et al have suggested an important role for iPLA2γ 
in mitochondrial functioning and energy metabolism in cardiac myocytes. Fasted 
transgenic mice over expressing iPLA2γ in myocytes exhibit exercise-associated 
ventricular dysfunction (159). The onset of this dysfunction correlates with increased 
expression of diacylglycerol acyltransferase I (DGATI) and massive accumulation of 
triglyceride accumulation, a signature of lipotoxicity. Indeed, the mitochondria of 
iPLA2γ transgenic animals are structurally compromised and exhibit reduced respiratory 
control quotient compared to wild type mitochondria. Mitochondrial function is also 
compromised in iPLA2γ knock out mice which exhibit reduced Complex IV-mediated 
oxygen consumption, likely due to decreased levels of tetra C18:2 cardiolipin in 
mitochondria (143).  These animals also exhibit reduced cold tolerance, decreased 
exercise capacity, and fail to gain weight after adolescence, all indications of 
compromised energy balance secondary to the loss of iPLA2γ. Together, these 
observations suggest that iPLA2γ plays an important role in maintenance of proper 
mitochondrial function and energy homeostasis. As such, a more detailed understanding 
of this enzyme may be necessary for development of drugs designed to restore energy 
balance in diabetes and other disorders related to obesity and the metabolic syndrome. 
 
F. iPLA2 in Neurological Diseases 
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iPLA2β is highly expressed in the brain and is the most highly expressed PLA2 in the 
hippocampus (304). Several recent studies have implicated iPLA2β in a variety of 
neurological processes, ranging from neural development to neuron survival, to neural 
transmission. For example, the selective iPLA2 inhibitors BEL and  palmitoyl 
trifluoromethyl ketone, (PACOCF3) increase the amplitude of -amino-3-hydroxy-5-
methylisoxazole-4-propionate (AMPA) receptor-mediated excitatory postsynaptic 
currents in hippocampal CA1 pyramidal cells (305). iPLA2 inhibitors suppress 
endothelin-induced Schwann cell proliferation and also reduce viability in primary 
cultures of rat cortical neurons, suggesting a role for the enzyme in survival of neuronal 
cells (305;306). It is well-documented that PLA2 activity is elevated in patients with 
schizophrenia (307;308). A recent report has associated first-episode schizophrenia with 
increased calcium-independent PLA2 activity in serum (309). At first glance, this 
observation appears to exclude iPLA2, as the enzyme is cytosolic and not secreted by 
viable cells. However, the observation of significant allelic and genotypic associations 
between iPLA2β polymorphisms and schizophrenia (307) underscore the possibility that 
iPLA2 may be a susceptibility gene for the disease. Perhaps the strongest association 
between iPLA2 and neurological disease is in diseases associated with iron 
accumulation in the brain. Both Infantile Neuroaxonal Dystrophy (INAD), a 
neurodegenerative disease associated with psychomotor regression and hypotonia and 
Neurodegeneration with Brain Iron Accumulation (NBIA) have been associated with 
inactivating mutations in the iPLA2β gene (310;311). Importantly, iPLA2β knockout 
mice develop neurological impairment by ~13 months of age (312). This impairment is 
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associated with the formation of spheroids containing tubulovesicular membranes, a 
characteristic of INAD in humans.  These observations provide strong support for the 
hypothesis that iPLA2 activity is essential for proper neurological development and 
brain function. They also underscore the need to identify the products of the iPLA2 
reaction that are involved in neurological development, as these molecules may be 
candidates for drug development in the future. 
 
VII. Summary and Perspectives 
There is accumulating evidence that the biological functions of iPLA2 are not limited to 
GPL homeostasis (Table 1). As described, iPLA2 has a variety of biomedically relevant 
activities, ranging from glucose and energy homeostasis to adipocyte and hepatic 
biology, to proliferation and chemotherapy-induced apoptosis of tumor cells, to the 
pathogenesis of Pseudomonas aeruginosa, to sperm motility (313) among others 
(Figure 6). Most of these effects are likely due to bioactive lipids derived from the 
products of the iPLA2 reaction, unesterified fatty acid and lysophospholipid. However, 
it is possible that the iPLA2 protein has catalysis-independent functions due to protein-
protein interactions mediated by its N-terminal ankyrin repeats.  For applications in 
which enhanced iPLA2 activity is likely to have therapeutic benefit (fatty liver, insulin 
sensitivity, apoptosis in response to chemotherapeutic drugs, INAD), detailed 
lipidomics analyses are warranted to identify the relevant bioactive lipids, their 
receptors, and the signaling mechanisms by which they control cell responses. In the 
design and implementation of such studies, it is imperative to recognize the relevant 
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bioactive lipids are likely to vary with cell/ tissue type and also with the nature of the 
stimulus. For applications in which iPLA2 inhibition is indicated (proliferation of cancer 
cells, Pseudomonas aeruginosa pathogenesis, chronic inflammation due to macrophage 
activation), it is important to develop more selective inhibitors, as BEL inhibits 
phosphatidate phosphohydrolase as well (314). Receptor antagonists are another 
potential strategy in cases where the relevant bioactive lipids have been identified. 
Known receptors for bioactive lipids range from G protein coupled plasma membrane 
receptors to nuclear hormone receptors that directly regulate transcription (315-317). As 
the iPLA2 enzymes are ubiquitous and have essential roles in lipid homeostasis, any 
iPLA2-directed drug strategy must be carefully designed and have exquisite selectivity 
for target cells and tissues.  One must also consider the potential for iPLA2 inhibitors to 
suppress innate immune responses by compromising macrophage function. Hence, 
although iPLA2 is an attractive drug target for a variety of diseases, the design and 
implementation of such strategies is likely to be a technical and intellectual challenge.  
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Table 1: Biological Functions of iPLA2
Biological Function Specific Application References 
Acyl chain 
remodeling 
(136;143;159;184-190) 
Regulation of 
Glycerophospholipid 
Mass 
(161;192-194) 
Glycerophospholipid 
Metabolism 
Arachidonic acid 
metabolism and 
eicosanoid production 
(171;172;204-212) 
Innate Immunity (213-224) Pathogenesis and Host 
Response Pathogenesis of Pseudomonas 
(132;225-232) 
Calcium Signaling 
and Homeostasis 
 (131;157;164;233-240) 
Apoptosis (150;151;219;244-246;248-
252;256;257;260;261) Cell Proliferation, Survival, and 
Apoptosis Survival, Growth, and Proliferation 
(189;195-198;257;262-264;268) 
Glucose-stimulated 
Insulin Secretion 
(7;15;136;187;189;276;286;287;291) 
Adipocyte/ hepatocyte 
Biology 
(178) 
Metabolism 
Mitochondrial 
function and energy 
homeostasis 
(143;159) 
Neurological 
Development and 
Function 
 (304-312) 
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Figure 6: Biological Activities of iPLA2 and Relevance for Drug Design and 
Targeting. Accumulating evidence indicates that the biological function of iPLA2 is not 
limited to basal GPL metabolism. The enzyme impacts on a several biomedically 
relevant processes and as such is an attractive drug target for a variety of disorders. 
However as iPLA2 expression is ubiquitous and the enzyme has important roles in basal 
metabolism, such strategies must be carefully designed to ensure targeting to 
appropriate cells and tissues. 
 
 
  61  
The novel PI3K inhibitor PX-866 
 
PI3K phosphorylates membrane phosphatidylinositides (PI) to generate PI(3,4,5)P3 that 
interacts with Akt via its PH domain and subsequently leads to activation of Akt by 
phosphorylation of ser473 (318;319).  PI3K consists of a heterodimer formed by a 
catalytic p110 subunit and a regulatory p85 subunit that is activated by receptor tyrosine 
kinase or G-protein coupled receptors (318;320;321).  Isoforms alpha and beta of the 
p110 subunit are distributed among many mammalian tissues (21).  Three genes encode 
eight splice variants of the p85 subunit (322); however there is no preference of any of 
the p110 catalytic subunit for any of p85 subunit (21).  Activation of the PI3K/Akt 
pathway is associated with cell survival and cell proliferation (318).   
 A variety of transformed cells frequently exploit the PI3K/Akt signaling 
pathway (318;323-327) often via constitutive activation of PI3K (328;329) as a means 
of survival. Downstream activation of Akt by PI3K confers resistance to apoptosis 
(330;331).  Therefore considerable interest has accumulated to determine the efficacy of 
targeting this pathway with chemotherapeutics.  Wortmannin, a fungal metabolite, and 
the flavonoid derivative LY294002 are PI3K inhibitors frequently used to inhibit the 
PI3K/Akt pathway and in turn, transformed cell growth and proliferation (318;332).  
LY294002 is a competitive inhibitor of the ATP-binding site on PI3K (318).  
Wortmannin inhibits the alpha and beta p110 subunit and has an IC50 that is 
approximately 500-fold lower than LY294002 (318;333).  While wortmannin is a potent 
inhibitor of PI3K, it and LY294002 demonstrate poor pharmacokinetics and high 
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hepatotoxicity thereby mitigating their efficacy as in vivo inhibitors of PI3K and 
diminishing their clinical value (334).   
 In the last several years, the Powis laboratory has synthesized the semisynthetic 
viridin PX-866, a wortmannin derivative (Figure 7) which exhibits potent antitumor 
activity and significantly lower toxicity in comparison to wortmannin (21;334-336).  In 
vivo, PX-866, an inhibitor of the p110alpha subunit of PI3K, exhibited negligible 
hepatotoxicity and demonstrated 80% inhibition of ser473-Akt phosphorylation in HT-
29 colon tumor xenografts at low nanomolar concentrations (21).   The IC50 of PI3K by 
PX-866 is approximately 10-fold lower than that of wortmannin and exhibits an 
intraperitoneal-injected maximum tolerated dose (MTD) of 19.5 mg/kg in C57BL/6 
mice in comparison to an MTD of 3.0 by wortmannin (21).  Hyperglycemia, reduced 
glucose tolerance and transient hyperinsulinemia lasting six hours following 
admininstration, however, were observed in vivo (335).  Further studies demonstrated 
that PX-866 treatment induces decreases in cancer cell motility and growth (334) and 
potentiates the antitumor activity of the epidermal growth factor receptor inhibitor, 
gefitinib (335).  In examining a potential role for activation of SREBP by the PI3K/Akt, 
we were prompted to employ this compound in several experiments designed to study 
its effects on lipid metabolism while appreciating the potential for its effect on insulin 
and glucose metabolism.   
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Figure 7:  Chemical structures of Wortmannin and its derivative PX-866 (21) 
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Rationale for studies: 
 The ability of lipids to influence cell signaling and function highlights the 
importance of studies that characterize the mechanisms, whether biological or chemical, 
that influence lipid metabolism.  At the systemic level, the liver is crucial to 
maintenance of lipid homeostasis and is the site at which these many of these biological 
processes occur.  Clearly, the study of lipid metabolism and the effectors involved is 
broad in scope.  Nonetheless, the studies presented here are an attempt to characterize 
the effect on hepatic lipid metabolism by several distinct biological entities: replication-
deficient Adenovirus-5, the group VIA calcium-independent phospholipase A2 and the 
novel phosphatidylinositol 3-kinase inhibitor PX-866. 
 
Author’s note:  Unless, otherwise noted, the following studies emphasize and refer to 
SREBP1c when the term “SREBP1” is used. 
 
  
 
. 
 CHAPTER 2: The influence of replication-deficient adenovirus-
5 on hepatic lipid metabolism 
 
 
 
Abstract:  Adenovirus 5- (Ad-5) based expression systems are commonly used to 
investigate the functions of gene products in cell lines and animal models. Recent 
reports have associated viral and other microbial infections with changes in metabolism 
and dyslipidemia. These observations prompted the hypothesis that replication-deficient 
Ad-5 might augment lipid synthesis in liver. To test this hypothesis, C57BL/6 mice 
were infected with first generation replication deficient Ad-5 and screened for hepatic 
and plasma triglyceride levels and expression of lipogenic genes and gene products. Ad-
5 infection induced transient hypertriglyceridemia together with increased expression of 
sterol regulatory element binding protein-1 (SREBP1) and its target genes in the 
triglyceride synthesis pathway. Unlike Hepatitis C Virus (HCV), another liver-directed 
virus associated with hepatic dyslipidaemia, Ad-5 infection selectively targeted 
SREBP1, as no changes were observed in SREBP2 or cholesterol levels. Ad-5-infected 
HepG2 human hepatoma cells and primary rat hepatocytes also exhibited increased 
expression of SREBP1 and its targets, suggesting that the virus induced dyslipidemia 
through direct effects on the liver. Ad-5 infection induced phosphorylation of Akt in 
HepG2 cells and livers of infected mice. Selective inhibitors of phosphatidylinositol 3-
kinase (PI3K) suppressed induction of SREBP1 and hypertriglyceridemia in cultured 
cells and Ad-5 infected mice. Together, these studies support the emerging concept of 
 65
  66  
virus-induced dyslipidemia and suggest a possible link between Ad-5 infection and 
hepatic steatosis. These data also raise concerns about use of replication-deficient Ad-5 
expression systems to study lipid metabolism in the liver. 
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Introduction 
 
There is accumulating evidence that supports a relationship between changes in 
metabolism, dyslipidemia, fatty liver disease, and increased obesity with viral 
(97;98;100), bacterial (101;102), and parasite (103)  infections.  Hepatitis C virus 
(HCV) infection, in particular is strongly associated with insulin resistance, non-
alcoholic fatty liver disease (NAFLD) and increased expression of lipogenic genes in 
hepatocytes (98;104).   Adenovirus-36 (Ad-36) infections are also correlated with 
aberrant lipid metabolism (116;117) and adenovirus-5 (Ad-5) induces adiposity in mice 
(118).  Replication-deficient adenoviruses, particularly adenovirus-5 (Ad-5), are widely 
used as expression vectors for gene transfer in vitro and in vivo (20).   Viral replication 
is not necessary for Ad-36 induction of adipogenesis (337), suggesting that replication-
deficient adenovirus may have the same lipogenic effects as does wild type. 
Replication-deficient adenoviruses have become indispensable tools for 
molecular biologists and are widely used as expression vectors in vitro and in vivo (20).  
Of the 51 currently identified serotypes of human adenoviruses, adenovirus-5 (Ad-5) 
has been extensively characterized and in its replication-deficient form is widely 
employed for transgene expression for in vitro and in vivo studies.  Replication-
deficient Ad-5 is the most commonly used adenovirus-based transgene expression 
vector (113).  Like HCV, Ad-5 primarily targets the liver when administered 
intravenously (20).   Given the major role of liver in systemic lipid metabolism, we 
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hypothesized that replication-deficient Ad-5 engineered for expression of exogenous 
genes would induce dyslipidemia in infected mice.   
 
Materials and Methods 
Materials 
Cell cuture reagents were obtained from Invitrogen or Hyclone.  PX-866, Oil Red O and 
thyroxine were obtained from Sigma.  Calpain Inhibitor I was obtained from Biomol.  
Antibodies were obtained from Cell Signaling Technology (total Akt and phospho-Akt , 
ser473), BD Biosciences (SREBP1 and FAS), Calbiochem (actin), and Pierce (HRP-
coupled secondary antibodies).  All qPCR primers and probes were purchased from 
Integrated DNA Technologies.  All first-generation replication-deficient adenovirus-5 
constructs lacking early genes E1 and E3 were obtained from the Massey Cancer Center 
Virus Vector Shared Resource facility of the Virginia Commonwealth University 
Medical Center.  
 
Mice 
C57BL/6 mice obtained from the Jackson Laboratory were housed on a reverse 
light/dark cycle and provided standard chow and water ad libitum except where 
indicated otherwise.  Eight to ten-week-old mice weighing approximately 20-25 grams 
were infected by tail-vein injection with 1 x 10E11 particles of adenovirus-5 expressing 
beta-galactosidase.  Mice were sacrificed at 2 to 5 days after infection.  The inhibitor 
PX-866 at a dose of 12.5 mg/kg or vehicle was administered by tail-vein injection 3 to 4 
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hours prior to infection.  Another injection of PX-866 or vehicle was administered 2 
days after infection.  PX-866 dissolved in DMSO was administered using a total vehicle 
volume of 100 uL PBS containing 20% DMSO.  Mice were sacrificed by 
exsanguination.  Livers were excised and flash frozen.  Plasma was collected.  Mice 
were maintained in accordance with Virginia Commonwealth University Institutional 
Animal Care and Use Committee standards. 
 
Plasma and lipid analysis 
~100 mg of liver tissue was homogenized in 1 mL of PBS. Lipids were extracted 
according to the method of Folch (338), dried under nitrogen, and dissolved in PBS 
containing 1% Triton X-100 (339).  Triglyceride and total cholesterol were quantified 
with colorimetric assay kits from Wako Diagnostics:  L-Type TG H and Cholesterol E, 
respectively and normalized to starting liver mass.  Plasma triglyceride, cholesterol, 
ALT, AST, Alkaline Phosphatase and glucose were quantified by the diagnostic 
laboratories of the McGuire Veterans Affairs Hospital, Richmond, VA.  Plasma insulin 
was analyzed with the Mercodia Mouse Insulin ELISA. 
 
Cell culture 
HepG2 human hepatoma cells (ATCC) were maintained in Dulbecco’s Modified Eagle 
Medium or Dulbecco’s Modified Eagle Medium without glucose for kinetic analysis of 
Akt phosphorylation (Gibco) supplemented with 10% heat-inactivated fetal calf serum, 
1% penicillin/streptomycin, 2 mM glutamine, 1 mM sodium pyruvate and 0.1 mM non-
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essential amino acids.  Primary rat hepatocytes were isolated from Harlan Male 
Sprague-Dawley rats (200-300 g) as described previously (340;341) and plated on 
collagen-coated plates. Rat hepatocytes were maintained in William’s E Media 
(Hyclone) supplemented with 1% penicillin, 0.1 µM dexamethasone, and 1 µM  
thyroxine.  All cell cultures were maintained at 7.5% CO2 humidity and 37oC.  Rats 
used were maintained in accordance with Virginia Commonwealth University 
Institutional Animal Care and Use Committee standards. 
 
Infection and treatments of HepG2 and primary rat hepatocytes 
HepG2 cells were plated at 5 x 105 to 106 cells/well in 6-well plates. Primary rat 
hepatocytes were plated at 50% confluence on six-well collagen-coated plates.  Cells 
were infected with cesium chloride purified empty replication-deficient adenovirus-5 at 
the indicated MOI.  After 16-20 hours, virus-containing media was removed and cells 
were cultured in fresh media until approximately 72 hours post infection. For kinetic 
analysis of Akt phosphorylation, HepG2 cells were infected at an MOI of 15 and 
harvested at the indicated times for time points up 72 hours post infection. For cells not 
harvested in the first 15 hours, virus was removed and media was replenished at 15 
hours post infection for the remaining time points. HepG2 cells or primary rat 
hepatocytes were pre-treated with the indicated concentrations of PX-866, Ly294002, or 
DMSO vehicle for one hour before infection with replication-deficient Ad-5 at MOI 15 
and 2.5 for HepG2 cells and primary rat hepatocytes, respectively. After overnight 
infection in the presence of inhibitors or vehicle, Ad-5 was removed.  Fresh media, 
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inhibitors and vehicle were replaced daily until harvest at approximately 72 hours post 
infection.  DMSO concentration never exceeded 0.04 percent. 
 
Protein Analysis by immunoblot 
Mouse liver homogenates were prepared from ~15 mg liver.  Using a dounce 
homogenizer, tissue was homogenized in a buffer containing 10 mM HEPES, pH 7.4, 
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 50 mM NaF, 30 mM Na4P2O7, 20 mM 2-
glycerophosphate, 1 mM activated Na3VO4 s, 1 % SDS supplemented with a 
phosphatase inhibitor cocktail I (Sigma) and a complete protease inhibitor cocktail 
(Roche).  HepG2 cells and primary rat hepatocytes were incubated with 25 µg/ ml 
calpain inhibitor I for two hours prior to harvest.  Cell homogenates were prepared in 20 
mM Tris-HCl, pH 7.5, 50 mM NaCl, 50 mM NaF, 30 mM Na4P2O7, 20 mM 2-
glycerophosphate, 1 mM activated Na3VO4, 5 mM EDTA, 2 mM EGTA, 1% SDS 
supplemented with a complete protease inhibitor cocktail (Roche).  Proteins were 
separated by SDS-PAGE followed by immunoblotting with the antibodies described 
above.  Immunoreactive proteins were detected with chemiluminescence (ECL kit from 
Amersham or Femto kit from Pierce) which was captured on X-ray film. Signals were 
quantified by densitometry (Alpha Inotech FC8800) and mean ± of the densitometry 
signals is shown below the blot. 
 
RNA Analysis by Quantitative reverse transcriptase PCR 
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Mouse liver RNA was prepared using the SV Total RNA Isolation System (Promega).  
mRNA encoding SREBP1, SREBP2 and ACC were screened by SYBR Green qPCR 
using the Brilliant QRT-PCR Core Reagent Kit, 1-Step (Stratagene).  rRNA encoding 
18S served as an internal control and was screened using the TaqMan, One-Step RT-
PCR Master Mix Reagents (Applied Biosystems).  Primers described previously (342) 
were as follows:  SREBP1, sense 5’-CACTGAAGCAAAGCTGAATAAATCTG-3’, 
antisense 5’-AGTGATTTGCTTTTGTGTGCACTT-3’; SREBP2, sense 5’-
CAAGAGAAAGTTCCTATCAAGCAAGTG-3’, antisense 5’-
GTCCTTCAACTCTATGATTTTGTCGTT-3’; ACC, sense 5’-
AGGATTTGCTGTTTCTCAGAGCTT-3’, antisense 5’-
CAGGATCTACCCAGGCCACAT-3’.  Primers and probe for 18S described 
previously (343) were: sense 5’-AAAATTAGAGTGTTCAAAGCAGGC-3’, antisense 
5’- CCTCAGTTCCGAAAACCAACAA-3’, probe CY5- 
CGAGCCGCCTGGATACCGCAGC-BHQ-2.  Differences in the fold levels of mRNA 
were calculated based on the standard curve method.  The standard curve was generated 
using a mouse liver RNA sample from one mouse used in the experiment.      
 
Oil Red O staining 
HepG2 cells were fixed and stained with Oil Red O according to Laughton (344).  In 
brief, cells were washed with PBS and fixed using 2% (v/v) perchloric acid.  Fixed cells 
were stained with Oil Red O dissolved in 1,2-propanediol at 2 mg/mL and prepared as 
previously described (344).  Images of stained cells at 20X mgnification were collected 
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with an Olympus DP12 digital microscope camera.  The experiment was repeated three 
times. 
  
Statistical Analysis 
All in vitro experiments were repeated at least three times.  The mean ± standard 
deviation of three determinations is shown.  The student’s t-test with p < 0.05 as a 
cutoff for statistical significance was used. Three to eight mice were studied for each in 
vivo condition.  The mean ± standard error is shown. Mann-Whitney two-sided U test 
with p < 0.05 as a cutoff for statistical significance was used to analyze data generated 
from in vivo experiments unless otherwise indicated. 
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Results 
To begin to test the hypothesis the Ad-5 infection increases hepatic lipid 
synthesis, C57BL/6 mice were infected by tail-vein injection with replication-deficient 
Ad-5 expressing β-galactosidase (β-gal), a commonly used in vivo and in vitro control 
vector for exogenous gene expression (20).  Mice were sacrificed 4 and 5 days post 
infection. Livers and plasma were screened for lipid and proteins associated with lipid 
metabolism. Compared to uninfected mice, mice infected with Ad-5 exhibited elevated 
plasma triglyceride on day 4 (Figure 8A) and elevated hepatic triglyceride (Figure 8C) 
on days 4 and 5 after infection with Ad-5.  In contrast, infected and uninfected mice 
exhibited similar levels of plasma and hepatic cholesterol. Synthesis of fatty acids and 
triglycerides is regulated by sterol regulatory element binding protein-1 (SREBP1), a 
helix-loop-helix lipid-regulated transcriptional activator that is synthesized as a ~125 
kDa precursor and processed to its ~68 kDa transcriptionally active form in lipid-
depleted cells (25). Hence, Ad-5 could increase triglyceride synthesis through increased 
SREBP1 expression, processing, or both. To test the hypothesis that Ad-5 elevated 
triglyceride through induction of SREBP1, we screened liver homogenates for 
expression of SREBP1. Livers of Ad-5 infected mice expressed precursor SREBP1 
protein at higher levels than did uninfected livers (inset, Figure 8B), suggesting that 
Ad-5 induced SREBP1 at the expression level.  
To confirm this observation, we used real time PCR (qPCR) to quantify 
SREBP1 transcripts in livers of control and Ad-5 infected mice.                               
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SREBP1 transcripts were significantly elevated in livers of infected mice on day 4 post 
infection (Figure 8B). The effect was transient, as SREBP1 expression returned to 
baseline by day 5.  Transcripts encoding acetyl-CoA carboxylase (ACC), a SREBP1 
target gene that encodes an essential enzyme in the fatty acid/ triglyceride biosynthetic 
pathway (25), were elevated in infected mice at day 4 and 5 (Figure 8B) suggesting that 
Ad-5 infection increased levels of transcriptionally active mature SREBP1 protein as 
well.  Together, these data indicate that infection with replication-deficient Ad-5 
induces a transient hypertriglyceridemia secondary to increased SREBP1 expression. 
These changes in lipid metabolism are in contrast to those in transgenic mice expressing 
mature SREBP1 which exhibit elevated hepatic triglyceride but reduced plasma levels 
of this lipid  (54). Over expression of SREBP1 in the transgenic model is a chronic 
change that may prompt adaptive responses that temper plasma triglyceride levels. The 
increase in plasma triglyceride that we observe is likely an acute response to infection 
with replication-deficient Ad-5 that is transient because the replication-deficient virus 
induces only a single round of infection. 
Control and infected livers exhibited similar levels of transcripts encoding 
SREBP2, a lipid-regulated transcriptional activator that induces enzymes associated 
with cholesterol synthesis (25) (Figure 8D). This observation was consistent with the 
unchanged cholesterol mass in Ad-5 infected livers (Figure 8B).  Importantly, the Ad5-
induced changes in hepatic lipid metabolism largely preceded frank hepatotoxicity, as 
plasma levels of alanine aminotransferase (ALT) and alkaline phosphatase (alkphos) 
were similar in control and Ad-5-infected mice on day 4 post infection (Figure 8E).  
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Aspartate aminotransferase (AST) was slightly elevated on day 4; however, this 
increase was modest compared to that observed on day 5. Effects of adenovirus 
infection on SREBP1 and lipid metabolism were more modest on day 5 than day 4. This 
could be related to the more substantial liver damage that occurs on day 5 post 
infection.  Together, these data indicate a selective induction of triglyceride synthesis in 
Ad-5 infected livers. Furthermore, these observations clearly distinguish effects of Ad-5 
from those of HCV, as HCV infection is associated with reduced serum cholesterol and 
no change in serum triglyceride levels (98;345). In contrast to our observations, another 
group has reported no changes in plasma or liver triglyceride in response to control Ad-
5 vectors (346).  The reason for this apparent contradiction is unclear at present, but 
may be related to differences in viral dose, laboratory chow, or other issues. 
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Figure 8: Replication-deficient Ad-5 induces SREBP1, its target genes, and 
hypertriglyceridemia in mice. C57BL/6 mice were infected with 1011 particles of first 
generation Ad-5 expressing β-gal or mock infected with saline and sacrificed at day 4 or 
5 post infection. (A) Quantification of lipids in plasma.  (B) Quantification of liver 
lipid, expressed as mg lipid per g of liver.  (C) Quantification of hepatic SREBP1 and 
ACC RNA.  Inset, liver homogenates from uninfected and Ad-5-infected mice 
sacrificed at day 4 were screened for SREBP1 by immunoblot.  Mean ± standard 
deviation (SD) of the densitometry signals normalized to actin is shown above blot.  (D)  
Quantification of hepatic SREBP2 RNA. SREBP1, SREBP2, and ACC RNA was 
normalized to 18S RNA and is expressed as relative mRNA expression, with uninfected 
mRNA set at 1.0. (E)  Quantification of ALT, AST and Alk Phos in plasma. * p < 0.05 
compared to uninfected. Three or four mice were studied in each group. 
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Figure 8A 
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Figure 8C 
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We next addressed the mechanism of replication-deficient Ad-5 induction of 
SREBP1 and hepatic triglyceride.  Because reports suggest that HCV, another virus that 
targets liver and augments lipid synthesis, induces changes in adiponectin, insulin, and 
glucose levels (347-349) that could increase hepatic SREBP1 expression, we could not 
discount the possibility that Ad-5 induced hepatic SREBP1 by increasing glucose or 
insulin levels in mice. However, control and Ad-5 infected mice showed no difference 
in levels of insulin and glucose four days post infection.  In fact, plasma glucose was 
significantly decreased at day 3 (Figure 9).  At day 4, non-fasting mean plasma glucose 
was 280 ± 42 mg/ dl for uninfected mice and 285 ± 10 mg/ dl for Ad-5 infected mice 
(seven mice/ group), whereas non-fasting mean plasma insulin was 1.4 ± 0.9 mg/dL for 
uninfected mice and 1.3 ± 0.4 mg/dL for Ad-5 infected mice (three mice/ group).  These 
observations prompted the hypothesis that Ad-5 directly interacts with liver cells and 
triggers signaling events that culminate in induction of SREBP1.   
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Figure 9:   Replication-deficient Ad-5 decreases plasma glucose in mice.  C57BL/6 
mice were infected with 1011 particles of first generation Ad-5 expressing β-gal or mock 
infected with saline and sacrificed at day 2 or 3 post infection.  Error bars represent 
mean ± standard deviation (n =4).  * p < 0.05.  
Glucose * 
 mg/dL 
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  We performed experiments to determine whether Ad-5 directly interacts with 
liver cells and triggers signaling events that culminate in induction of SREBP1.  HepG2 
human hepatoma cells and rat primary hepatocytes were infected with replication-
deficient Ad-5. Cells were cultured in the presence of Ad-5 for approximately 16 hours, 
subsequently cultured in the absence of virus and analyzed 72 hours from the start of 
infection.  Fixed cells were stained with Oil Red O to detect triglycerides and other 
neutral lipids. As shown in Figure 10A, infected HepG2 cells exhibited increased Oil 
Red O staining at relatively modest multiplicity of infection (MOI). Whole cell 
homogenates were prepared and screened for SREBP1, SREBP2, and fatty acid 
synthase (FAS), another SREBP1 target and enzyme in the fatty acid/ triglyceride 
synthetic pathway. HepG2 cells and primary hepatocytes infected with Ad-5 
demonstrated robust increases in expression of SREBP1 (Figure 10B-C). Expression of 
FAS, a target of SREBP1 was also increased in infected cells (Figure 10D, data not 
shown) again indicating increased levels of the transcriptionally active mature form of 
SREBP1 in infected cells. Similar results were obtained with “empty” Ad-5 vector 
(shown) and Ad-5 expressing green fluorescent protein (data not shown).  In contrast, 
Ad-5 infection had no effect on SREBP2 expression (data not shown), consistent with 
the observation that neither SREBP2 (Figure 8D) nor plasma cholesterol was elevated 
in Ad-5-infected mice (Figure 8A). Together these data indicate that like HCV, Ad-5 
induces lipid synthesis through direct interaction with hepatocytes (350;351).   
However, they also further underscore the differences between Ad-5 and HCV, as HCV 
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infection induces both SREBP1 and SREBP2 in Huh7 human hepatoma cells (350). 
HCV core protein induces expression, processing, and phosphorylation of both SREBP1 
and SREBP2  and thereby expression of their target genes (350-352). In addition, HCV 
core protein suppresses the activity and/ or expression of microsomal transport protein 
(MTP), thereby reducing the assembly and secretion of VLDL (353). Although we 
cannot rule out an effect of replication-deficient Ad-5 on MTP at present, elevated 
plasma triglyceride levels suggest that the SREBP1 is a major target of the virus and 
that induction of this protein results in the hypertriglyceridemia observed in Ad-5 
infected mice.  
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Figure 10: Replication-deficient Ad-5 induces SREBP1, its target genes, and 
neutral lipid accumulation in cells. HepG2 cells and primary rat hepatocytes were 
infected with replication-deficient Ad-5 at various multiplicity of infection (MOI, 
shown). (A) HepG2 cells were stained with Oil Red O to detect neutral lipids. Shown 
are fields from a representative experiment. The experiment was performed three times. 
(B and C) Immunoblot of SREBP1 in homogenates of (B) HepG2 cells and (C) primary 
rat hepatocytes. (D) Immunoblot analysis of FAS in homogenates of HepG2 cells. All 
immunoblot signals were quantified by densitometry and normalized to actin. Fold 
change in SREBP1 or FAS (mean ± SD relative to uninfected cells) from three separate 
experiments is shown below each blot.  A representative blot is shown.  * p < 0.05, ** p 
< 0.01, *** p < 0.001 compared to uninfected.  
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Figure 10D 
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We next addressed the molecular mechanism of replication-deficient Ad-5 
induction of SREBP1. Ad-5 infection has a selective effect on SREBP1 and its targets 
and does not impact SREBP2 expression or function. These observations are 
reminiscent of the effects of insulin, another selective inducer of SREBP1.  
Phosphatidylinositol 3-kinase (PI3K) and its downstream effectors Akt and the atypical 
protein kinases C ζ and λ are components of the insulin signaling pathway that are 
essential for insulin-stimulated lipid and glycogen synthesis as well as the inhibition of 
gluconeogenesis (88;89).  HCV infection activates the PI3K/ Akt pathway in Huh 7 
hepatoma cells (350). Notably, other investigators have observed PI3K/Akt activation in 
response to replication-deficient Ad-5 infection (111;112).  These observations 
prompted the hypothesis that Ad-5 induces SREBP1 by activating the PI3K/ Akt 
pathway. To test this hypothesis, HepG2 cells were infected with replication-deficient 
Ad-5 at MOI 15 and screened for phosphorylated Akt as a measure of PI3K/ Akt 
activation.  A sustained increase in Akt phosphorylation was observed starting at 12 
hours and extending through at least 72 hours post infection (Figure 11A).  Levels of 
phosphorylated Akt were also elevated in livers of Ad-5 infected mice (Figure 11B) 
due to both increased Akt mass (ratio total Akt/ actin = 0.16 ± 0.01, uninfected; 0.26 ± 
0.02, infected, p = 0.029) and increased phosphorylation of Akt protein (ratio 
phosphoAkt/ total Akt= 17± 0.6, uninfected and 27 ± 1, infected, p= 0.057). To our 
knowledge, the induction of Akt expression is unique to Ad-5 and is not observed in 
other viral infections. At present, we are uncertain why Akt protein increases in the 
livers of Ad-5 infected mice but not in infected HepG2 cells. However, the data suggest 
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that Ad-5 infection increases the pool of activated Akt both infected mice and cultured 
cells. To directly test the hypothesis that Ad-5 induces SREBP through PI3K/Akt, we 
treated hepatocytes and C57BL/6 mice with Ly294002 or PX-866, a wortmannin analog 
(21;336)  before infection with replication-deficient Ad-5.  Both Ly294002 and PX-866 
suppressed Ad-5 induction of SREBP1 in cultured hepatocytes (Figure 11C and D).  
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Figure 11: Replication-deficient Ad-5 activates SREBP1 via the PI3K/Akt pathway 
which is involved in induction of lipogenesis. (A) HepG2 cells were infected with 
replication-deficient Ad-5 (MOI 15) and harvested at the indicated times. Homogenates 
were screened for total and phosphorylated Akt. A representative experiment is shown. 
A representative experiment is shown. The bar graph below shows mean and standard 
deviation (error bars) of the ratio of phosphorylated Akt/ total Akt (white) or total Akt/ 
actin (black) in three experiments. * p < 0.05 compared to uninfected; ** p < 0.01 
compared to uninfected.   (B) Liver homogenates from vehicle-treated mice were 
screened for total and phosphorylated Akt and actin by immunoblot. The ratios of 
phosphorylated/ total Akt, phosphorylated Akt/ actin and total Akt/ actin (relative to 
uninfected mice) are shown below the blots. (C) HepG2 pre-treated with the indicated 
concentrations of PX-866, Ly294002, or DMSO vehicle for one hour before infection 
with replication-deficient Ad-5 at MOI 15.  Cells were cultured in the presence of 
inhibitors or vehicle for the duration of the experiment and were harvested at 
approximately 72 hpi.  Cell homogenates were prepared and screened for SREBP1 by 
immunoblot.  Signals were quantified by densitometry and normalized to actin (loading 
control).  Percent inhibition of Ad-5-induced SREBP1 activation is shown below blot. 
A representative experiment is shown (n = 2). (D) Immunoblot analysis of SREBP1 in 
primary rat hepatocytes treated as in (C) normalized to actin. Infection MOI = 2.5.  
Lanes: 1: vehicle, uninfected; 2: vehicle, Ad-5; 3: 30 µM PX-866, Ad-5; 4: 15 µM PX-
866, Ad-5; 5: 20 µM Ly294002, Ad-5; 6: 10 µM Ly294002, Ad-5. Percent inhibition of 
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Ad-5-induced SREBP1 activation is shown below blot. A representative experiment is 
shown (n = 2). 
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PX-866 induces transient increases in plasma insulin (21).  Despite these 
potential confounding effects that would be expected to increase SREBP1 expression, 
PX-866 suppressed SREBP1 (p=0.0058, Figure 12A) and hypertriglyceridemia 
(p=0.006, Figure 12B) induction by Ad-5 to levels that were not statistically different 
from uninfected controls.  Furthermore, PX-866 treatment induced little or no liver 
damage, as assessed by plasma ALT, AST, and alk phos levels (Figure 12C).
 Figure 12: Inhibition of the PI3K/Akt pathway blocks Ad-5 induced lipogenesis in 
vivo. (A-C) C57BL/6 mice were pretreated with 12.5 mg/kg PX-866 or DMSO before 
infection with replication-deficient Ad-5 and sacrificed on day 4 post infection (A) 
Quantification of hepatic SREBP1 RNA, normalized to 18S RNA. The data are 
expressed as relative mRNA expression, with uninfected, vehicle-treated mice set at 
1.0. (B) Quantification of plasma triglyceride (mg/ dl). Each symbol represents one 
mouse. Horizontal bar is mean of the group.  * p < 0.05 compared to Ad-5, vehicle-
treated;   # p < 0.05 compared to uninfected, vehicle-treated.  (C) C57BL/6 mice were 
treated as shown. Plasma was harvested 4 days post infection and assessed for ALT, 
AST, and Alkphos. Data presented are the mean of “n” determinations and error bars 
are the standard error of the mean. * statistically different from vehicle, uninfected (p < 
0.05). 
 97
  98  
Figure 12A 
 
Figure 12B 
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Figure 12C 
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Discussion 
 This report characterizes previously unreported effects of replication-deficient Ad-5 on 
hepatic lipid metabolism: induction of the PI3K/ Akt pathway, increased expression of 
SREBP1 and its targets, increased hepatic triglyceride, and hypertriglyceridemia. These 
observations distinguish effects of Ad-5 from those of HCV, as HCV infection is 
associated with reduced serum cholesterol and no change in serum triglyceride 
(98;345). Ad-5-induced hyperlipidemia also differs from that of transgenic mice 
expressing mature SREBP1 which exhibit elevated hepatic triglyceride but reduced 
plasma levels of this lipid  (54). Over expression of SREBP1 in the transgenic model is 
a chronic change that may prompt adaptive responses that temper plasma triglyceride 
levels. In contrast, the increase in plasma triglyceride that we observe is likely an acute 
response to Ad-5 infection.  
The molecular mechanism of PI3K activation by replication-deficient Ad-5 is 
unclear at present. The observations that circulating insulin levels are reduced in 
infected mice and that Ad-5 induces SREBP1 in cultured hepatocytes argue against a 
systemic effect and suggest that Ad-5 induces SREBP1 through direct interaction with 
hepatocytes. Another group C adenovirus, adenovirus-2 (Ad-2), activates PI3K and Akt 
when its penton base binds αv integrin (354;355). Other studies suggest that E4-ORF1 
protein is required for PI3K activation by Ad-5 (356). As our replication-deficient 
adenoviruses retain both the penton base and E4-ORF1, additional experiments are 
necessary to delineate the mechanism of PI3K activation in our system. 
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We are not certain if induction of SREBP1 is common feature of adenovirus 
infection or a specific response to infection with Ad-5. Like Ad-5, Ad-2 activates PI3K  
making it likely that this group C adenovirus also induces SREBP1 and hepatic lipid 
synthesis (354;355). Ad-9 and Ad-36 (group D adenoviruses) also activate the PI3K 
pathway through E4-ORF1 (357;358), suggesting that SREBP1 may be induced by 
group D adenoviruses as well. Group D adenoviruses have other well-established 
effects on systemic lipid metabolism including induction of adipogenesis and obesity in 
a variety of animal models (358-360). These observations suggest that Ad-5 could 
promote obesity as well, a hypothesis that is supported by recent studies with wild-type 
Ad-5 in outbred CD1 mice (118). Thus, Ad-5 has a variety of effects on systemic 
biology that could contribute to development of the metabolic syndrome.  This 
hypothesis merits further investigation. 
Activation of the PI3K targets PKCζ and PKCλ is necessary for insulin-
mediated induction of SREBP1 (89;361). Constitutively active PKCλ but not Akt 
induces SREBP1 in livers of wild type mice and restores SREBP1 expression in livers 
of p85α/ p85β double knock out mice to wild type levels (89). These observations 
prompt the hypothesis that the induction of SREBP1 by Ad-5 may be mediated through 
PKCζ/ λ. Although classical PKC is activated in Ad-2-infected HeLa cells (362), there 
are no reports of PKCζ/ λ activation in response to Ad-5 infection. Our preliminary 
experiments indicate that neither PKCζ nor PKCλ is phosphorylated upon Ad-5 
infection (data not shown), but additional experiments are necessary to verify these 
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observations and confirm that PKCζ/ λ is not involved in Ad-5-mediated induction of 
SREBP1. 
Replication-deficient Ad-5 has become an indispensable expression vector for 
gene transfer and has been used in  gene-therapy clinical trials (20). Our observations 
prompt concerns regarding the use of Ad-5 expression vectors.  The negative control for 
such studies is often “empty” Ad-5 or Ad-5 expressing irrelevant protein. Our data 
highlight the importance of uninfected controls in these experiments.   
Other investigators have demonstrated increased adiposity in Ad-5 infected mice 
and that other serotypes of adenovirus, infect adipocytes and induce adipogenesis and 
obesity (118;360). Our work is an important extension of these studies, as we 
demonstrate that adenovirus infection also alters lipid metabolism in the liver. These 
observations prompt the hypothesis that wild-type Ad-5 contributes to the etiology of 
fatty liver disease.  Nearly 50% American adults have antibodies against Ad-5, 
indicating previous infection with the virus (363).  It is tempting to speculate that some 
fatty liver disease patients develop this disorder secondary to adenovirus infection. 
Transgenic mice expressing transcriptionally active SREBP1 develop fatty liver  due to 
increased synthesis of fatty acids and triglycerides (53;54). Patients infected with 
replication-competent Ad-5 could have chronically high levels of SREBP1, resulting in 
increased hepatic triglyceride synthesis and fatty liver. Additional studies are required 
to test this hypothesis and determine whether adenovirus infection is a risk factor for 
fatty liver disease. 
 
  
 
Chapter 3: The group VIA calcium-independent 
phospholipase A2 as a novel regulator of sterol regulatory-
element binding proteins 
 
 
 
Abstract: 
Aberrant lipid metabolism underlies the complications of lipid disorders. Sterol 
regulatory element-binding proteins (SREBP) are transcription factors that regulate the 
transcription of genes involved in lipid metabolism. SREBP undergoes posttranslational 
processing from an inactive precursor to an active mature form. Exogenous unsaturated 
fatty acids (UFA) suppress SREBP processing, expression and SREBP-mediated gene 
expression. To date, an endogenous source of UFA capable of modulating SREBP is 
elusive. Localized to the same compartment as precursor SREBP, Group VIA calcium-
independent phospholipase A2 (iPLA2) releases UFA from the sn-2 position of 
glycerophospholipids.  We hypothesized that iPLA2 provides endogenous UFA to 
suppress SREBP-mediated transcription. siRNA and chemical inhibitors were used to 
suppress iPLA2 and plasmid and adenovirus strategies were used to overexpress iPLA2 
in CHO and HepG2 cells. iPLA2 inhibition increased both SREBP expression and 
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SREBP-mediated transcription. In contrast, iPLA2 overexpression attenuated SREBP 
expression and SREBP-mediated transcription. This decline in SREBP correlated with 
reduced expression of SREBP target genes and attenuated overall fatty acid synthesis in 
HepG2 cells. These data support the hypothesis that iPLA2 generates endogenous UFA 
that limit SREBP function and suggest that this enzyme may hold therapeutic promise 
to treat the various diseases that stem from lipid dysregulation. 
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Introduction 
Many of the genes encoding enzymes involved in fatty acid, triglyceride, and 
cholesterol synthesis contain sterol response elements (SRE) that allow for feedback 
regulation of expression (25;47;48).  SREs promote gene expression when they are 
bound by sterol regulatory element binding proteins (SREBPs), members of the basic-
helix-loop-helix family of transcription factors.  The SREBPs are encoded by two 
genes, generating SREBP1 and SREBP2 proteins.  The SREBP1 gene has two 
transcription start sites, which generate two forms of SREBP1: SREBP1a and 
SREBP1c.  In general, SREBP2 regulates genes involved in cholesterol synthesis and 
metabolism while SREBP1a and 1c are more closely associated with the synthesis of 
fatty acids and triglycerides.  SREBP1c appears to be the most relevant isoform in 
primary cells while cultured cells express primarily SREBP1a.  In sterol loaded cells, 
SREBP proteins are inactive and tethered to the ER membrane through two 
transmembrane segments and an association with SREBP cleavage activating protein, 
SCAP.  When sterol levels decline, SCAP dissociates from the ER resident protein Insig 
and promotes translocation of SREBP from the ER to the golgi apparatus (57;58).  Two 
golgi-associated proteases, the site-1 and site-2 proteases, release the basic-helix-loop-
helix portion of SREBP that then translocates to the nucleus to induce gene expression.  
Hence, SREBP processing is an essential event in the regulation of lipid synthesis and 
metabolism in the liver and this event is subject to feedback regulation by sterols.  
Other investigators have demonstrated that SREBP processing is suppressed by 
exogenous polyunsaturated fatty acids (PUFA), that PUFA augments sterol suppression 
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of SREBP processing, and that SREBP1c expression is suppressed when PPAR-α binds 
PUFA derivatives (39;43;79;84;364).  Like sterols, PUFAs suppress SREBP 
translocation from ER to golgi and thereby prevent processing and generation of 
mature, transcriptionally active SREBP (39;43;79).   The effect of PUFAs appears to be 
largely specific for SREBP1 (76;80), although fish oil, a rich source of PUFA, also 
suppresses SREBP2 (365). Thus, PUFAs selectively suppress expression of SREBP1 
targets, including fatty acid synthase (FAS), acetyl CoA carboxylase (ACC), and other 
genes associated with fatty acid and triglyceride synthesis.  SREBP1c expression is 
another potential target for PUFAs and their derivatives through PPAR-α-dependent 
suppression of liver X receptor- (LXR)-mediated transcription of the SREBP1 gene 
(84;364). Together, these data indicate PUFA as a potential mechanism for controlling 
SREBP1 activation and thereby disorders associated with dyslipidemia such as fatty 
liver disease, cardiovascular disease, diabetes, and metabolic syndrome. Indeed, diets 
rich in PUFAs have been associated with decreased risk for atherosclerosis and 
cardiovascular disease (366;367). 
All of these observations are derived from studies in which exogenous PUFAs 
are added to cultured cells or to the diets of laboratory animals.  Although mammalian 
cells do not synthesize PUFA, these molecules are taken up from the diet and stored in 
neutral lipids and glycerophospholipids.  Thus, glycerophospholipid can be viewed as a 
reservoir of PUFAs that might be released to regulate lipid synthesis and lipoprotein 
assembly by hepatocytes. The group VIA phospholipase A2 (iPLA2), is a lipid hydrolase 
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that attacks the sn-2 ester bond of glycerophospholipids releasing lysophospholipid and 
unesterified fatty acid, often PUFA (37;368).  
Recent reports suggest that iPLA2 has major roles in insulin mobilization and fat 
metabolism.  Glucose-stimulated insulin production is suppressed when insulinoma 
cells are treated with an inhibitor of iPLA2 (287). In addition, iPLA2 knock out mice 
exhibit impaired insulin secretion in response to glucose and forskolin and exaggerated 
hyperglycemia when treated with streptozotocin (136).  Furthermore, these mice exhibit 
increased glucose intolerance when fed a high-fat diet (136).  Conversely, iPLA2 over 
expressing cells exhibit increased insulin secretion in response to glucose stimulation 
(287;291).  iPLA2 overexpression augments ER stress in insulinoma cells thereby 
promoting apoptosis of a major source of insulin (369).  Furthermore, recent studies 
suggest a role for iPLA2 in adipogenesis, as terminal differentiation of 3T3-L1 
preadipocytes is blocked when iPLA2 expression is suppressed with siRNA and iPLA2 
expression is elevated in the adipose tissues of obese Zucker rats (178).    
Given its connection to lipid and insulin metabolism, it seems reasonable to 
propose a role for iPLA2 in the regulation of SREBP.  We hypothesize that the reaction 
catalyzed by iPLA2 is an endogenous source of PUFAs that suppress SREBP and 
thereby regulate the expression of genes that are controlled by  SREBP (153;368). To 
test this hypothesis, we generated HepG2 human hepatoma and Chinese hamster ovary 
(CHO) cells with enhanced or reduced iPLA2 activity. Our studies indicate that 
SREBP1 expression, transcriptional activity, and expression of SREBP1 target genes is 
suppressed in cells with high levels of iPLA2 and that reduced iPLA2 activity is 
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associated with increased SREBP1 expression, activity and target gene expression. 
Together, these studies suggest iPLA2 as a novel target for the control of SREBP1 and 
thereby lipid disorders associated with its target genes. 
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Materials and Methods 
Materials 
Chinese Hamster Ovary (CHO) 7 cells were received from Dr. Joseph L. Goldstein 
(University of Texas Southwestern Medical Center).  HepG2 cells were obtained from 
the ATCC.  All siRNA was constructed using an online siRNA design engine provided 
by Qiagen and obtained from Qiagen-Xeragon.  Primers employed in the design of 
adenoviral vectors for overexpression of iPLA2 were obtained from Integrated DNA 
Technologies.  The pSyn SRE luciferase construct was provided by Dr. Gregorio Gil 
(VCU Medical Center) and Dr. Timothy Osborne (University of California at Irvine).  
Luciferase and β-galactosidase activity was measured using the Tropix Dual-Light Kit 
from Applied Biosystems.  N-acetyl-leucyl-leucyl-norleucinal (Calpain Inhibitor 1) and 
bromoenol lactone (BEL) were purchased from Biomol International.  1-Palmitoyl-2-
[14C] palmitoyl-sn-glycero-3-phosphocholine (DPPC) and [14C] acetate were purchased 
from Amersham Biosciences and New England Nuclear, respectively.  Unlabeled DPPC 
was purchased from Avanti Polar Lipids.  Cell culture reagents were obtained from 
Invitrogen.  Fatty acid-free bovine serum albumin and all organic reagents were 
purchased from Sigma Chemical Company.  iPLA2 polyclonal antiserum, monoclonal 
anti-SREBP-1 and 2 and polyclonal anti-ERK 1 were obtained from Cayman Chemical, 
BD Pharmingen/BD Biosciences and Santa Cruz Biotechnology, Inc., respectively.  
Secondary antibodies conjugated to horseradish-peroxidase were obtained from Pierce.  
All first-generation replication-deficient adenovirus-5 constructs were obtained from the 
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Massey Cancer Center Virus Vector Shared Resource facility of the Virginia 
Commonwealth University Medical Center.  
 
Cell Culture 
 CHO7 cells were maintained in DMEM/F12 supplemented with 10% heat inactivated 
fetal calf serum, 100 units/mL penicillin, 100 mg/mL streptomycin, and 2 mM 
glutamine.  For lipid depletion of CHO7 cells, cells were cultured in 1% BSA in lieu of 
10% heat inactivated fetal calf serum.  HepG2 human hepatoma cells (ATCC) were 
maintained in Dulbecco’s Modified Eagle Medium or Dulbecco’s Modified Eagle 
Medium (Gibco) supplemented with 10% heat-inactivated fetal calf serum, 1% 
penicillin/streptomycin, 2 mM glutamine, 1 mM sodium pyruvate and 0.1 mM non-
essential amino acids.  All cell cultures were maintained at 7.5% CO2 humidity and 37 
degrees C.   
 
Mice 
C57BL/6 mice obtained from the Jackson Laboratory were housed on a reverse 
light/dark cycle and provided standard chow and water ad libitum except where 
indicated otherwise.  Eight to ten-week-old mice weighing approximately 20-25 grams 
were infected by tail-vein injection with 1 x 10E11 particles of adenovirus-5 expressing 
beta-galactosidase or iPLA2.  Mice were sacrificed at 4 days after infection by 
exsanguinations.   Livers were excised and flash frozen.  Mice were maintained in 
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accordance with Virginia Commonwealth University Institutional Animal Care and Use 
Committee standards. 
 
Inhibition and overexpression of iPLA2 
iPLA2 was inhibited with BEL, a suicide inhibitor highly specific for iPLA2 (146;210) 
and siRNA.  BEL was resuspended in DMSO at a stock concentration of 25 mg/mL.  
Cells were incubated with BEL for the indicated times and concentrations of BEL.  The 
siRNA for iPLA2 targets the CHO iPLA2 sequence 5’-
AACCCACATAGTGGCTTCCGA-3’.  Control siRNA was used to control for the 
effects of exogenous oligonucleotides.  siRNA was transfected per the manufacturer’s 
instructions using Lipofectamine 2000 (Qiagen).  Cells treated with siRNA were plated, 
allowed to adhere and treated with siRNA at time zero and retransfected 48 hours later 
with harvest for western, iPLA2 activity assay or luciferase assay occurring at 
approximately 72 hours.  iPLA2 overexpression in HepG2 cells was achieved using 
replication deficient Ad-5 lacking E1 and E3.  In brief, CHO iPLA2 was cloned into the 
pZerotg-CMV vector that was used for insertion into replication-deficient Ad-5 
performed by the Massey Cancer Center Virus Vector Shared Resource facility of the 
Virginia Commonwealth University Medical Center.  HepG2 cells were plated at 5 x 
105 to 106 cells/well in 6-well plates.  Cells were infected with cesium chloride purified 
empty Ad-5 or Ad-5 expressing GFP or expressing iPLA2 at the indicated MOI in a 
volume of 700 uL.  After 16-20 hours, virus-containing media was removed and cells 
were cultured in fresh media until time of harvest.  iPLA2 overexpression was achieved 
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in CHO7 cells using a “CFP-iPLA2” construct in which CHO iPLA2 was inserted into 
the pECFP-c1 vector provided by Dr. Robert Tombes, Virginia Commonwealth 
University, Dept of Biology.  CHO7 cells were plated in 6-well plates at 5 x 105 cells 
per well and transfected in accordance with manufacturer’s instructions with CFP-
iPLA2 using Fugene 6 (Roche). 
 
iPLA2 activity assay   
CHO7 cells were harvested and cell homogenates were prepared by resuspending 
pelleted cells with a buffer consisting of 10 mM HEPES, pH 7.4, 0.34 M sucrose, 10 
µg/mL leupeptin, 10 µg/mL aprotinin, 1 mM PMSF followed by sonication on ice.  
iPLA2 activity was analyzed by an activity assay as described (161). Briefly, equal 
amounts of protein were incubated for two hours at 40 degrees C with a substrate 
consisting of 100 µM DPPC, 400 µM Triton-X 100, with 0.02 µCi labeled DPPC added 
as a tracer.  Assays were processed and released palmitic acid was quantified according 
to the method of Dole (370).  Each experimental sample was run in duplicate. 
 
Measurement of Luciferase activity 
The pSyn SRE construct containing a generic TATA element and three SREs of the 
hamster HMG CoA synthase gene fused into a luciferase vector was cotransfected with 
a B-galactosidase reporter to control for transfection efficiency.  The pSyn SRE and β-
gal constructs were transfected per the manufacturer’s instructions using Lipofectamine 
2000 (Qiagen).  For experimentation using siRNA, the pSYN SRE construct was 
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cotransfected with siRNA at 48 hours (siRNA treatment alone at time zero and 
cotransfected at 48 hours with the pSYN SRE construct).  Cells were then harvest for 
luciferase analysis at approximately 24 after transfection with the pSYN SRE construct.  
For overexpression studies, the pSYN SRE construct was cotransfected with the 
overexpression construct and cells were assayed approximately 16 hours after 
transfection.  Following the indicated treatment and transfection and incubation times of 
CHO7 cells with the pSYN SRE reporter and β-galactosidase (β-gal) construct, 
luciferase and β-gal activity were assayed per the manufacturer’s instructions using the 
Tropix Dual-Light Kit (Applied Biosystems). 
 
Protein extraction and immunoblotting 
Mouse liver homogenates were prepared from ~15 mg liver.  Using a dounce 
homogenizer, tissue was homogenized in a buffer containing 10 mM HEPES, pH 7.4, 
10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA, 50 mM NaF, 30 mM Na4P2O7, 20 mM 2-
glycerophosphate, 1 mM activated Na3VO4, 1 % SDS supplemented with a phosphatase 
inhibitor cocktail I (Sigma) and a complete protease inhibitor cocktail (Roche).  
Following the indicated treatment, CHO7 or HepG2 cells received 25 µg/mL calpain 
inhibitor 1 and were harvested as described (43).  Equal amounts of protein in whole 
cell homgenates were resolved on a 10% SDS-polyacrylamide gel (tris-glycine gel) and 
transferred to a supported nitrocellulose membrane (Bio-Rad) followed by blocking 1 hr 
to overnight in 5% non-fat dry milk suspended in tris-buffered saline (TBS) with 0.02% 
Tween 20.  Following blocking, blots were incubated overnight with primary 
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antibodies, washed 3 times with TBS, incubated 2 hr with a secondary horseradish 
peroxidase conjugated antibody and washed 3 times.  An enhanced chemilluminescent 
detection reagent (Amersham Biosciences) and subsequent detection of 
chemiluminescence using x-ray film were used to analyze the immunoblot.  Primary 
antibodies for SREBP and iPLA2 were obtained from BD Pharmingen and Cayman 
Chemical, respectively.  ERK 1 antibody used to control for protein loading was 
obtained from Santa Cruz Biotechnology.       
 
Measurement of Fatty Acid Synthesis  
To analyze fatty acid synthesis as described, HepG2 cells were plated at 5 x 105 cells 
per well in 6-well plates, with three wells/ treatment group.  Cells were pulsed with 0.5 
µCi/mL [14C] acetate for two hours and harvested as described previously (371).    
Radiolabeled cells were washed one time with PBS, solubilized with 500 µL of 0.5M 
NaOH, and transferred to glass tubes.  Saponification was achieved using 1.5 mL of 
EtOH and 250 µL of 50% (w/v) KOH.  100 µL aliquot was removed for protein 
quantification and analysis of total cell [14C] acetate uptake.  The remaining sample was 
incubated 1 hr at 60 degrees C.  500 uL were then acidified (pH < 3.0)—approximately 
65 µL 10N HCL--and followed by extraction with 1 mL of hexane.  Following 
vortexing, the organic layer was extracted and subjected to scintillation counting.  The 
raw data were normalized by protein mass and are expressed as the cpm/µg protein.   
 
Statistical Analyses   
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Experiments were repeated three times in most instances.  A representative example is 
shown.  Where applicable, the mean ± standard deviation of three determinations is 
shown and the student’s t-test with p < 0.05 as a cutoff for statistical significance was 
used to analyze the data shown. 
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Results 
 
iPLA2 over expression suppresses SREBP1 expression and activity 
Other investigators have demonstrated suppression of SREBP1 expression and 
processing by exogenous unsaturated fatty acids (39;75) . The goal of this investigation 
was to determine if endogenous iPLA2-derived fatty acids had the same effect. To test 
this hypothesis, we developed a recombinant adenovirus expressing CHO iPLA2 and 
examined the effects of its overexpression in HepG2 human hepatocarcinoma cells. 
HepG2 cells have relatively modest levels of endogenous iPLA2 (Figure 13A). 
However, the adenovirus increased iPLA2 expression in a dose dependent manner and 
increased catalytic activity was evident at relatively modest multiplicity of infection 
(MOI) (Figure 13 A and B). HepG2 cells were infected with wild type adenovirus 
(MOI 50) or iPLA2 adenovirus, cell homogenates were prepared, and SREBP1 protein 
expression assessed by immunoblot analysis.  As shown in Figure 14, SREBP1 
expression inversely correlated with expression of iPLA2.  Despite the increases in 
SREBP1 following Ad-5 infection of hepatocytes as detailed in Chapter 2, the data in 
Figure 14 indicate that iPLA2 overexpression using Ad-5 attenuates this Ad-5-induced 
expression of SREBP1.  It can be assumed that Ad-5 lacking the iPLA2 gene is itself 
increasing SREBP1 expression.  C57BL/6 mice infected with Ad-5 expressing iPLA2 
also demonstrated decreased hepatic expression of SREBP1 in response to iPLA2 
overexpression (Figure 15).  Again, while Ad-5 is shown to increase SREBP1 in vivo, 
insertion of the iPLA2 gene in Ad-5 inhibits this outcome.  Interestingly, of mature and 
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precursor SREBP1, levels of precursor SREBP1 were the most profoundly reduced in 
response to iPLA2 overexpression. This observation prompted experiments to determine 
if iPLA2 overexpression correlated with reduced SREBP transcriptional activity that is 
facilitated by mature SREBP.  Experiments to determine whether iPLA2 overexpression 
inhibits SREBP-mediated transcription are ongoing.  Preliminary findings begin to 
support that hypothesis that iPLA2 overexpression indeed inhibits SREBP 
transcriptional activity.    
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Figure 13: Overexpression of iPLA2 in HepG2 cells with recombinant adenovirus 
Adenovirus-mediated over expression of iPLA2 in HepG2 cells. HepG2 human 
hepatoma cells were infected with empty adenovirus or recombinant adenovirus 
expressing iPLA2 and harvested approximately 72 hours post infection. Cell 
homogenates were prepared and screened for iPLA2 expression (A) or catalytic activity 
(B). Expression of ERK 1/2 was quantified as a loading control for the immunoblot. A 
representative experiment is shown 
(n=2).
A 
B 
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Figure 14: iPLA2 suppresses SREBP1 expression in HepG2 cells 
HepG2 cells were infected with control adenovirus expressing GFP (MOI 50, lane 1) or 
adenovirus expressing iPLA2 at  MOI 5 (lane 2), MOI 20 (lane 3), or MOI 50 (lane 4). 
Cell homogenates were prepared and screened for SREBP1 by immunoblot. ERK1/2 is 
a  loading control (n=1). 
 
 
 
 
                    GFP            iPLA2        iPLA2        iPLA2
 
MOI             50                  5               20             50 
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Figure 15:  Overexpression of iPLA2 in C57BL/6 mice results in decreased hepatic 
 immunoblot for SREBP1.  Each lane represents one mouse of 
e indicated experimental group.  
 
SREBP1 expression 
C57BL/6 mice were infected with 1 x 1011 particles of Ad-5 expressing iPLA2 or beta-
gal (control).  Mice were sacrificed at 4 days post infection and liver homogenates were 
prepared and analyzed by
th
 
 
β-galiPLA2
mSREBP1
pSREBP1
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iPLA2 suppresses expression of SREBP1 target genes 
The observations in Figures 14 and 15 prompted experiments to determine if iPLA2 
sion of FAS, an SREBP1 target associated with 
ynthesis of fatty acids and triglycerides (53). As shown in Figure 16, iPLA2 
overexpression correlated with reduced SREBP transcriptional activity.  Therefore, as a 
surrogate marker for SREBP1 transcriptional activity, an immunoblot strategy was used 
to screen HepG2 cells infected with empty control Ad-5 or recombinant Ad-5 
overexpressing iPLA2 for expres
s
overexpression suppressed FAS expression. Importantly, the decline in FAS expression 
correlated with reduced fatty acid synthesis in HepG2 cells, as assessed by 
incorporation of [14C]-acetate into fatty acid (Table 2).  Shown are data from two 
independent experiments: an experiment in which cells were incubated in FCS-
containing media and one in which cells were incubated in delipidated media.  
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Figure  16: iPLA2 overexpression suppresses SREBP1 target genes in HepG2 cells 
 
 
HepG2 cells were infected with empty (MT) adenovirus or adenovirus expressing 
recombinant iPLA2. Cell homogenates were prepared and screened for expression of the 
SREBP1 targets FAS 72 hours post infection (n=1). 
 
FAS
ERK 1/2
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Table 2:  iPLA2 overexpression decreases fatty acid synthesis in HepG2 cells 
HepG2 cells were infected by with control empty Ad-5 or Ad-5 overexpressing iPLA2.  
Cells were assayed as described in “Materials and Methods” at 72 hours post infection.  
Cells subject to lipid-free conditions were incubated in delipidated media for 16 hours 
prior to incubation with [14C]-acetate.  *fatty acid synthesis expressed as cpm of 
incorporated [14C]-acetate /ug protein (n = 1 for experiment performed in presence and 
absence of lipid).  The experimental groups indicated as “lipid free” (second data set of 
three experimental groups) were cultured in lipoprotein-depleted serum containing 
media supplemented with 1% fatty-acid free BSA. 
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Analysis of SREBP1 in CHO cells overexpressing iPLA2 and in CHO cells with low 
LA2 activity 
isms controlling SREBP processing 
nd a variety of mutant CHO cell lines are available for the study of SREBP 
9;371;372). In addition, overexpression of iPLA2 in CHO cells as shown in Figure 
17A suppresses SREBP transcriptional activity in lipid-free conditions and FCS-
supplemented conditions (Figure 17B). Thus, CHO cells are an appropriate model to 
test the hypothesis that iPLA2 modulates SREBP1 expression and processing.  
Two strategies were used to suppress iPLA2 in CHO cells: iPLA2-specific siRNA and 
an iPLA2-selective inhibitor, bromoenolactone (BEL). The siRNA strategy strongly 
reduced iPLA2 expression and activity by approximately 80% vs. the enzymatic activity 
of control siRNA-treated cells (Figures 18A and 18B) and treatment with BEL, an 
suicide substrate inhibitor of iPLA2(184), suppressed iPLA2 activity in CHO cells to a 
similar degree (data not shown). 
iP
 
Together, these data in vivo and in HepG2 cells support the hypothesis that 
bioactive lipids generated downstream of the iPLA2 reaction suppress SREBP1 
expression and presumably processing based on the effect of iPLA2 overexpression on 
the SREBP1 gene target FAS and fatty acid synthesis. These observations prompted 
additional experiments to determine if the converse was true: if SREBP1 was induced in 
cells with low iPLA2 activity. As endogenous iPLA2 activity is low in HepG2 cells, an 
additional model was used to test this hypothesis, CHO cells. Other investigators have 
used this model extensively to delineate the mechan
a
(3
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Figure 17: iPLA2 overexpression suppresses SREBP transcriptional activity in 
CHO cells. 
(A) CHO cells were transiently transfected with plasmid encoding CFP-iPLA2 or 
control CFP.  Cell homogenates were prepared approximately 20 hours later and 
screened for iPLA2 activity. A representative experiment is shown (B) CHO cells were 
transiently cotransfected with plasmid encoding CFP-iPLA2 or control CFP and the 
pSynSRE reporter construct and β-gal control plasmid. Luciferase activity was 
quantified and normalized to β-gal control plasmid activity (promoter activity) 18 hours 
after transfection.  (Open bars represent culture conditions supplemented with fetal calf 
serum.  Closed bars represent culture conditions using media supplemented with fatty-
acid free BSA in lieu of fetal calf serum.)  Error bars represent the standard deviation 
of the mean of a representative experiment run in triplicate (experiment n=2).  
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Figure 17B 
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Figure 18: iPLA2 inhibition in CHO cells by siRNA 
ells were transfected with control siRNA or siRNA targeted to iPLA2.  Cells were C
treated with control or iPLA2-directed siRNA at time zero and 48 hours later.  Cells 
were harvested at approximately 72 hours.  (A) Immunoblot analysis of iPLA2 protein 
in cells transfected with control or iPLA2 siRNA. (B) iPLA2 activity in cells transfected 
with control or iPLA2 siRNA.  Representative experiments are shown.  
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Control siRNA-treated, iPLA2-treated cells, and vehicle-treated and BEL-treated cells 
P modulation 
y iPLA2 is dependent on its catalytic activity.  Emphasizing the potential relationship 
etween iPLA2 catalytic activity and SREBP, supplementing BEL-treated cells with 
d the effect of BEL and blocked the increase in transcriptionally active 
REBP (Table 3).  As expected, effects of BEL were reversed when cells were treated 
with exogenous oleic acid, an unsaturated fatty acid (data not shown). The induction of 
SREBP activity indicated that SREBP1 expression and/ or processing might be elevated 
in CHO cells with low iPLA2 activity. To test this hypothesis, CHO cells were treated 
with control siRNA or iPLA2-specific siRNA, cell homogenates were prepared, and 
SREBP1 expression was assessed by immunoblot. As shown in Figure 20, SREBP1 
expression was induced in CHO cells treated with iPLA2-specific siRNA. iPLA2 over 
expression in HepG2 cells (Figure 14) primarily affected levels of precursor SREBP1 
and a similar effect was observed in siRNA-treated CHO cells.  To better elucidate the 
effect on mSREBP1, experiments are planned to examine mSREBP1 in nuclear 
extracts.  However, the robust induction of SREBP transcriptional activity (Figure 19) 
suggests that modest changes in mature SREBP1 have significant impact on 
were transfected with the pSynSRE reporter and luciferase assays were performed to 
quantify SREBP-dependent transcriptional activity. As shown in Figure 19, pSynSRE 
reporter activity was ~ three-fold higher in CHO cells treated with iPLA2-specific 
siRNA compared to cells treated with control siRNA.  Similar results were obtained 
when CHO cells were treated with BEL (Table 3), indicating that SREB
b
b
oleate, an unsaturated fatty acid added to mimic the presence of an iPLA2 catalytic 
product, reverse
S
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transcriptional activity measured in the luciferase assay. 
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Figure 19: PSYN in CHO siRNAIPLA2-targeted siRNA decreases SREBP 
transcriptional activity in CHO cells 
CHO cells were transfected with control or iPLA2 siRNA at time zero and cotransfected 
with the same siRNA treatments and the pSynSRE reporter and β-gal control constructs 
at 48 hours.  Approximately 15 hours later, cells were harvested and luciferase activity 
was quantified and normalized to β-gal activity (promoter activity).  A representative 
experiment is shown.  Error bars represent the standard deviation of the mean of an 
experiment run in triplicate.  
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Table 3:  Chemical inhibition of iPLA2 increases SREBP1-mediated gene 
the pSYN SRE luciferase and β-gal control 
 
expression in CHO cells   
CHO cells were cotransfected with 
constructs.  Following transfection, cell were treated with 10 µM BEL and incubated in 
serum-supplemented media or delipidated media containing 1% fatty-acid free BSA for 
15 hours.  Cells were harvested and luciferase activity was analyzed and normalized to 
β-gal control promoter activity.  *Fold induction expressed as the ratio of the response 
in lipid-free conditions to FCS-supplemented conditions.  A representative experiment 
run in triplicate is shown. 
 
Treatment Fold Induction*
BEL 11.5
BEL + oleate 8.4
vehicle 7.0
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Figure 20:  iPLA2 suppression by siRNA  induces SREBP1 expression in CHO cells 
CHO cells were transfected with control siRNA or siRNA targeted to iPLA2 at time 
 
zero and 48 hours later.  Cell homogenates were prepared at approximately 72 hours 
later and screened for SREBP1 protein by immunoblot.  A representative experiment is 
shown. 
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Expression of the SREBP1 target gene FAS was suppressed when iPLA2 was 
over expressed in HepG2 cells (Figure 16). These observations prompted the 
hypothesis that SREBP target genes would be induced in CHO cells with low iPLA2 
activity. To test this hypothesis, homogenates of cells treated with control siRNA or 
iPLA2-specific siRNA were screened for FAS and ACC expression by immunoblot. As 
shown in Figure 21, expression of both gene products was induced in CHO cells with 
low iPLA2. Together, these data support the hypothesis that bioactive lipids derived 
from the iPLA2 reaction suppress SREBP1 expression and subsequently the SREBP1 
transcriptional regulation of its gene targets.   
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Figure
 
 
 21: iPLA2 suppression induces SREBP1 target genes 
CHO cells were transfected with control siRNA or siRNA targeted to iPLA2 at time 
zero and 48 hours later.  Cell homogenates were prepared at 72 hours and screened for 
the SREBP1 targets FAS and ACC (n=1).  
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Discussion 
Other investigators have demonstrated that unsaturated fatty acids suppress 
expression of SREBP1 target genes (39;75). We hypothesized that the unsaturated fatty 
acid products of iPLA2 would suppress SREBP1. In CHO and HepG2 cells, 
verexpression of iPLA2 suppresses SREBP-mediated transcription (Figure 17B) and 
xpression of the SREBP1-target FAS (Figure 16), respectively.  Conversely, SREBP1-
EK293 cells, reached a similar conclusion with data that also provide evidence for a 
prefential inhibitory effect by UFA on SREBP1 rather than SREBP2 (373).  In vivo 
studies also demonstrated similar effects on SREBP1 upon feeding of Sprague Dawley 
Rats diets enriched in UFA (374).  Based on these studies, (39) and preliminary 
fluorescence microscopy images alluding to localization of CFP-iPLA2 at the ER, the 
organelle to which precursor SREBP1 is bound, we originally hypothesized that iPLA2 
o
e
mediated transcription and expression of target genes was induced when iPLA2 
expression or catalytic activity was suppressed in CHO cells. Together, these data 
implicate iPLA2 as an endogenous source of unsaturated fatty acids that regulate 
SREBP1. 
 Evidence from several groups and from studies in various mammalian cells and 
organisms have characterized the effect of unsaturated fatty acids on SREBP1.  Using 
CHO, CV-1 and HepG2 cells, Worgall et al demonstrated that oleate and other UFA 
attenuated the transcriptional activation of SREBP (39).  The authors concluded that the 
effect of UFA on SREBP occurred at the level of processing from the transcriptionally 
inactive 125 kDa isoform to the transcriptionally active isoform.  Another study in 
H
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overexpression would inibit SREBP1 at the level of processing.  However, our results 
indicat
  
e an effect of iPLA2 largely on the expression of SREBP1.  Others have seen the 
effect of UFA on expression of SREBP1.  In an vivo study, Xu et al (374), observed 
decreases in hepatic SREBP1 mRNA in response to an UFA-enriched diet.  
Furthermore, a study using human colonic carcinoma CaCo-2 cells uncovered the effect 
of UFA on SREBP1 at the expression level (375).  Of course, cell type may play a role 
in whether the effect by UFA is at the level of expression or processing; however, our 
data from two distinct cell types indicate an effect at the level of SREBP1 expression 
that subsequently results in an effect on SREBP1-mediated transcription of its gene 
targets.      
 Although we hypothesize that iPLA2-derived UFA regulate SREBP1, these data 
do not rule out the possibility that the lysophospholipid released from iPLA2 catabolic 
activity participates partially or fully on the effect on SREBP1. To test this possibility, 
we can determine  whether the exogenous addition of lysophosphatidylcholine 
(LysoPC) or another lysophospholipid can attenuate the increase in SREBP1 expression 
in response to BEL treatment.  Currently, there is no evidence to demonstrate an effect 
by lysoPL on any SREBP isoform.  On the other hand, there is evidence that lysoPL 
could potentially have the opposite effect, as one study in HepG2 cells has 
demonstrated that treatment with lysoPC increased TG synthesis (376).  In light of this 
finding, our data argue that if iPLA2-generated lysoPC activates SREBP1, this effect is 
neglible compared to the suppressive effect of iPLA2-derived  UFA.  Conversion of 
LPC to LPA by a lysophospholipase D such as autotaxin could potentially mediate the 
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effects on SREBP1 via LPA binding to LPA receptors (267).  However, as LPA is a 
potent mitogen to which a majority of mammalian cells respond (38) it may be a poor 
inhibitor of SREBP1 because increases in cell growth require concomitant increases in 
lipid mass for daughter cells.  On the other hand, LPA binding to PPARγ, could limit 
LXR activation of SREBP1 expression via competition between PPARγ and LXR for 
RXR (90;364).  One phenotype of cancer cell progression gaining broader interest is 
overexpression of the SREBP1 target FAS (377).  In summary, while there is evidence 
to support the notion that iPLA2-generated lysoPC is not involved in inhibiting 
SREBP1, further experimentation is required to examine the relationships between 
SREBP1, iPLA2, LPA, LXR and PPARγ.   
 In characterizing the relationship between SREBP regulation and iPLA2, we 
questioned whether the catalytic activity resulting in iPLA2 catabolic products or the 
mere presence of iPLA2 influences SREBP1. The data in CHO cells treated with BEL 
(Table 3) indicate that iPLA2 enzymatic activity is required to affect SREBP1 
transcriptional activity.  Immunoblot analysis of CHO cells treated with BEL will 
indicate if indeed the effect remains at the level of expression.  To supplement the 
experiments using BEL, our laboratory has a catalytically inactive, dominant negative 
CHO iPLA2 mutant that can be overexpressed in CHO and HepG2 cells to test the 
hypothesis that iPLA2 catalytic activity is responsible for the effect on SREBP1.  
Implementation of this strategy to further characterize the relationship between iPLA2 
and SREBP1 is planned.  Alternatively, transient transfection of the endogenous 
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dominant alternatively spliced ankyrin protein can be used to study whether catalytic 
iPLA2 activity is responsible for the effect of this enzyme on SREBP. 
 Confusion occasionally arises in distinguishing SREBP1a from 1c.  Many 
papers refer only to SREBP1 presumably referring to SREBP1c.  SREBP1a is the 
isoform with the longer acidic N-terminal domain that is found in cultured cell lines and 
without preference activates both fatty acid and cholesterol synthetic genes (25).  
SREBP1c is highly expressed in vivo and in liver in particular and, as mentioned, 
preferentially activates genes in the fatty acid synthetic pathway (25).  Our data does 
not distinguish between SREBP1a and SREBP1c.  Several studies can be employed if it 
becomes necessary to distinguish between the two isoforms.  To truly determine a direct 
decrease sphingomyelin mass in the cell membrane (43).  This finding prompted 
effect on SREBP1a expression, an RNAse protection assay can be employed as has 
been described (91). Despite this unanswered question and because SREBP1c is the 
relevant and predominate isoform in liver and in vivo, it is clear that SREBP1c 
expression is inhibited by iPLA2 as indicated by our in vivo data (Figure 15).  To 
further characterize the effect of iPLA2 on SREBP, studies are planned to determine the 
effect, if any, of iPLA2 on SREBP2 and its gene targets employing similar methods 
detailed in this study.  This is an important follow up study as it could uncover a role for 
iPLA2 in the regulation of cholesterol. 
 There are several lines of evidence to support the mechanisms by which iPLA2 
may regulate SREBP1 as shown in this study.  Studies to determine the effect of UFA 
on SREBP found that exogenous UFA induce sphingomyelinase activity and therefore 
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speculation that loss of sphingomyelin mass in the cell membrane could lead to the 
release of free cholesterol from the cell membrane to the cytoplasm as sphingomyelin in 
a agonists potentially result in competition of 
the cell membrane stabilizes and acts to retain cholesterol in membranes (43).   
Therefore, released cholesterol due to increased sphingomyelinase activity could, in 
turn inhibit SREBP (43).  However, this SREBP regulation of cholesterol occurs at the 
level of processing and not expression.  Again, this mechanism may be one of the ways 
in which iPLA2 affects SREBP1.  Nonetheless, it cannot account for the effect we and 
others have observed at the level of SREBP1 expression.   
Several studies allude to the mechanism by which iPLA2-generated UFA might 
impact SREBP1 expression, specifically in the liver in which SREBP1c is the 
prominent isoform (25)(39;75;76).  It was discovered in vivo using LXR knockout mice, 
that LXR alpha and beta, which are activated by oxysterols, can selectively control the 
expression of SREBP1c (91).  A study concluded that SREBP1c gene expression 
mediated by the Liver X Receptor (LXR)/retinoid X receptor heterodimer may be 
inhibited by exogenous PUFA through activation of the nuclear receptor peroxisome 
proliferator-activated receptor (PPAR) alpha (364), a nuclear hormone receptor 
associated with activation of fatty acid beta-oxidation.  This study concluded that the 
presence PUFA and other PPAR-alph
PPAR-alpha with LXR for RXR dimerization, which is necessary for LXR to mediate 
SREBP-1c transcription.  Nonetheless, these findings have not been confirmed by other 
investigators.  The laboratory of Brown and Goldstein has presented evidence that UFA 
antagonize the agonist-induced activation of LXR that normally leads to increased 
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SREBP1 expression in cultured rat hepatoma cells (82).  These data prompt future 
studies to determine if iPLA2 suppress SREBP1 by targeting LXR alpha and beta and 
potentially via PPAR alpha.     
Finally, it is necessary to reconcile the data in Figures 14 and 15 with data 
presented in Chapter 2.  Figure 14 and 15 have no uninfected controls.  Based on the 
findings in Chapter 2, it can be assumed that Ad-5 itself is increasing SREBP1 
expression.  Therefore the baseline expression of SREBP1 is elevated in these 
experiments in which iPLA2 is overexpressed using Ad-5.  These findings may lead one 
to question whether iPLA2 can attenuate SREBP1 expression in the absence of Ad-5 
infection.  The use of conventional transfection methods to overexpress iPLA2 have 
been used as shown in Figure 17A and 17B and demonstrate that iPLA2 overexpression 
indeed attenuates, in this case, SREBP-mediated transcription.  Likely, overexpression 
of iPLA2 using conventional transfection methods to avoid elevating baseline SREBP1 
expression in HepG2 cells would result in decreased SREBP1 expression; however, 
these experiments have not been performed. 
Studies in iPLA2 knockout mice and INS-1 insulinoma cells have demonstrated the 
importance iPLA2 to proper glucose-stimulated insulin secretion in pancreatic islet cells 
and allude to the potential of iPLA2 modulation as a treatment for diabetes. Our data 
begin to highlight the potential therapeutic role for iPLA2 in the liver, specifically 
pathological aberrant lipid as in steatohepatitis.  iPLA2 generates unesterified 
arachidonic acid that can be metabolized into bioactive prostaglandins and leukotrienes 
(9).  These oxygenated derivatives could bind to cell surface receptors and augment the 
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inflammatory response that constitutes the “second hit” required for the development of 
steatohepatitis (9;378;379).  However, derivatives of arachidonic acid and other PUFA 
also bind the nuclear hormone receptor PPAR-γ and can suppress inflammation through 
this mechanism thereby limiting hit 2 (380;381). In addition, iPLA2-derived PUFAs 
suppress SREBP1 and expression of FAS, ACC, and other proteins involved in fatty 
acid and triglyceride synthesis, essential components of the first “hit” (25;79;364). Thus 
iPLA2-derived PUFA have the potential to block one of the processes that leads to 
triglyceride accumulation, steatosis and the dylsipidaemic pathologies arising from 
accumulation of triglycerides. In support of these speculations, other investigators have 
shown that dietary PUFA both suppress induction and reverse established steatosis 
(76;80;382;383).  We hypothesize that iPLA2 will be even more effective in this regard 
when it is activated in hepatocytes, as it will provide a continuous, local source of 
PUFA to suppress SREBP1c.  This study details the first endogenous sournce of UFA 
capable of regulating SREBP1 and, in turn, may allude to a new therapeutic target to 
treat dyslipidemia and its complications.     
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Chapter 4: The influence of the novel phosphatidylinositol 3-
metabolism 
 
 
Abstract: 
Insulin stimulates SREBP1 expression vi
kinase inhibitor PX-866 on systemic and hepatic basal lipid 
 
a the PI3K/Akt pathway in hepatocytes.  
Researchers relied on the use of phosphatidylinositol 3-kinase (PI3K) inhibitors to 
characterize this insulin-induced signaling event in hepatocytes.  The novel PI3K 
inhibitor PX-866, a wortmannin analog, is gaining recognition for its potency, potential 
as a chemotherapeutic and low in vivo toxicity relative to wortmannin and LY294002, 
two commonly employed PI3K inhibitors.  We recently showed that PX-866 attenuates 
replication-deficient adenovirus-5 induced activation of hepatic SREBP1 activation.  
This finding prompted us to hypothesize that PX-866 would influence basal hepatic 
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lipid metabolism and result in changes in circulating lipid levels.  In C57/BL6 mice 
dministered PX-866 we observed decreased plasma triglyceride and a trend towards 
ecreased hepatic SREBP1 expression without the presence of hepatotoxicity.  These 
ice also exhibited increases in circulating cholesterol, an event that requires further 
xamination.  These findings suggest that PX-866 is a novel regulator of basal lipid 
m
 
 
 
 
 
a
d
m
e
etabolism.  
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 Insulin regulates hepatic lipid metabolism through the induction of SREBP1 
(87;88).  This event promotes fatty acid and triglyceride synthesis and dampens glucose 
synthesis in the liver (25;87).  The role of PI3-kinase (PI3K) in insulin signaling has 
been well est
Introduction 
ablished (89;384). Inhibitors of this enzyme not only block SREBP1 
duction by insulin, but also prevent the down regulation of genes associated with 
luconeogenesis, resulting in impaired glucose tolerance and hyperinsulinemia (89).  
oupled with other studies, the use of these inhibitors has been responsible for 
ncovering the participation of the PI3K/Akt pathway in SREBP biology (62) and in 
sulin-induced activation of SREBP1 expression (88;385).  The two commonly used 
hemical inhibitors of PI3K are LY294003 and Wortmannin.  Wortmannin is among the 
most potent of these inhibitors. It is a pan-specific PI3K inhibitor that irreversibly 
suppresses catalytic activity by modifying a lysine in the active site (21). 
PX-866, an analog of wortmannin, represents a new PI3K inhibitor that exhibits 
increased biological stability, reduced hepatotoxicity, and 10-fold higher inhibitory 
activity against the enzyme (21).  PX-866 selectively inhibits the p110 alpha subunit 
isoform of PI3K.  While PI3K signaling is ubiquitous among cell types and has several 
roles in facilitating proper cell function, there is evidence to suggest that the catalytic 
p110 alpha isoform is involved in insulin activation of Akt (386).  Of the few published 
studies using PX-866, the focus has been on its potential as a novel chemotherapeutic as 
it demonstrates significant inhibition of Akt phosphorylation and cancer cell motility 
in
g
C
u
in
c
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and shows promise as an enhancer of epidermal growth factor receptor inhibitors used 
 of non-small cell lung cancer (21;334-336).  Despite this focus, only a 
d increases in 
triglyce
in the treatment
few studies have begun to characterize systemic effects of PX-866 in vivo.  Ihle et al 
showed that PX-866 induces transient hyperinsulinemia and impaired glucose tolerance, 
conditions that were reversed upon administration of metformin or when drug treatment 
was stopped (335).  This finding suggests that the compound may be an unsuitable 
candidate to study liver lipid metabolism as the inadvertent increases in circulating 
insulin due to PX-866 admininstration would, in effect, induce PI3K signaling in the 
hepatocyte.  On the other hand, it was possible that, at a proper dose, the increase in 
plasma insulin would be insignificant enough to allow for adequate in vivo inhibition of 
PI3K in the liver despite increases in plasma insulin.  Other studies in our laboratory 
showed that replication-deficient adenovirus-5 increases Akt activation (Chapter 2, 
Figure 11B) with increases in SREBP1 induction (Chapter 2, Figure 10C).  We also 
demonstrated that PX-866 was able to antogonize SREBP1 induction an
ride by replication-deficient adenovirus (Chapter 2, Figure 12A,B). As such, 
we hypothesized that PX-866 treatment would suppress basal lipid metabolism in 
C57BL/6 mice. 
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Materials and Methods:  
Materials 
PX-866 and DMSO was obtained from Sigma.  All qPCR primers and probes were 
purchased from Integrated DNA Technologies. 
 
Mice 
C57BL/6 mice obtained from the Jackson Laboratory were housed on a reverse 
light/dark cycle and provided standard chow and water ad libitum except where 
indicated otherwise, 12.5 mg/kg PX-866 or DMSO vehicle was administered by tail-
vein injection to eight to ten-week-old mice weighing approximately 20-25 grams.  
Inhibitor or DMSO control were administered in the a.m. at time zero and again at 48 
hours in the a.m.  Non-fasted mice were sacrificed at 96 hours from the beginning of 
treatment.  PX-866 dissolved in DMSO was administered using a total vehicle volume 
of 100 µL PBS containing 20% DMSO.  Mice were sacrificed by exsanguination.  
Livers were excised and flash frozen.  Plasma was collected.  Mice were maintained in 
accordance with Virginia Commonwealth University Institutional Animal Care and Use 
Committee standards. 
            
Plasma and lipid analysis 
Plasma triglyceride, cholesterol, ALT, AST, Alkaline Phosphatase and glucose were 
quantified by the diagnostic laboratories of the McGuire Veterans Affairs Hospital, 
Richmond, VA. 
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RNA Analysis by Quantitative reverse transcriptase PCR 
ere screened by SYBR Green qPCR 
sing the Brilliant QRT-PCR Core Reagent Kit, 1-Step (Stratagene).  mRNA encoding 
rved as an internal control and was screened using the TaqMan, One-Step RT-
ney two-sided U test with p < 0.05 as a cutoff for statistical 
nce was used. 
Mouse liver RNA was prepared using the SV Total RNA Isolation System (Promega).  
mRNA encoding SREBP1, SREBP2 and ACC w
u
18S se
PCR Master Mix Reagents (Applied Biosystems).  Primers described previously (342) 
were as follows:  SREBP1, sense 5’-CACTGAAGCAAAGCTGAATAAATCTG-3’, 
antisense 5’-AGTGATTTGCTTTTGTGTGCACTT-3’;  Primers and probe for 18S 
described previously (343) were: sense 5’-AAAATTAGAGTGTTCAAAGCAGGC-3’, 
antisense 5’- CCTCAGTTCCGAAAACCAACAA-3’, probe CY5- 
CGAGCCGCCTGGATACCGCAGC-BHQ-2.  Differences in the fold levels of mRNA 
were calculated based on the standard curve method.    
 
Statistical Analysis 
Three to eight mice were studied for each in vivo condition.  The mean ± standard error 
is shown. Mann-Whit
significa
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Results 
asal lipid metabolism, we 
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e to single outlier (p 
 
the major cholesterol transporter 
 mice, this suggests an increase in HDL cholesterol (HDL-C), a hypothesis that is 
 in the laboratory. PX-866 also increased plasma glucose (311 ± 
To test the hypothesis that PX-866 would influence b
treated mice with 12.5 mg/ kg PX-866 or DMSO vehicle by tail-vein injection every 48
hours for four days (two doses over four days).  Upon sacrifice, livers were harvest
and plasma collected and screened for aminotransferases and lipids. As shown in
Figure 22, triglyceride was reduced by ~29% (from 113 ± 9 mg/ dl to 80 ± 4 mg/ dl)
plasma of PX-866 treated mice (p=0.0122). We hypothesized that this reduction migh
be due to reduced expression of SREBP1. To test this hypothesis, SREBP1 mRNA 
livers of control and PX-866-treated mice was quantified with the qPCR strategy u
in Chapter 2. The PX-866-treated livers exhibited a trend towards reduced SREBP1 
expression (Figure 23) that did not reach statistical significance du
= 0.32). Interestingly, PX-866-treated mice also exhibited increased plasma cholesterol
(p=0.0006) (Figure 24). As high density lipoprotein is 
in
currently being tested
12 versus 374 ± 8, 20%, p= 0.0012, (Figure 25) in these non-fasted mice.   
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Figure 22:  Mice treated with PX-866 exhibit decreased plasma triglyceride 
Mice treated as described in “materials and methods.” Each symbol represents one 
mouse.  The horizontal bar depicts the mean for the mice of the experimental group. 
p=0.0122.  n=7. 
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Figure 23: Mice treated with PX-866 exhibit trend towards decreased hepatic 
izontal bar depicts the mean for the mice of the experimental group.  
0.32.  n=7. 
SREBP1 
Mice treated as described in “materials and methods.”  Each symbol represents one 
mouse.  The hor
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Figure 24:  PX-866 increases plasma cholesterol 
Mice treated as described in “materials and methods.”  Each symbol represents one 
mouse.  The horizontal bar depicts the mean for the mice of the experimental group.  
p=0.0006.  n=7. 
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Figure 25: PX-866 increases plasma glucose (non-fasted mice) 
Mice treated as described in “materials and methods.”  Each symbol represents one 
mouse.  The horizontal bar depicts the mean for the mice of the experimental group. 
p=0.0012. 
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Importantly, PX-866 induced changes in lipid metabolism occurred in the absence of 
5 mg/kg is well below the reported maximum tolerated dose (MTD) of 19.5 
g/kg via i.p. injection (21). Together, these data indicate that PX-866 alters basal lipid 
etabolism resulting in changes in resting plasma lipid levels. The reduction in baseline 
triglyceride levels prompted us to re-examine effects of PX-866 on Ad-5 induced 
hypertriglyceridemia. As shown in Figure 27, PX-866-treated mice still exhibited 
increased plasma triglyceride upon infection with replication-deficient adenovirus. 
However, PX-866 significantly attenuated Ad-5 induced hypertriglyceridemia (1.76 ± 
.042 fold versus 1.49 ± .164 fold induction, p = 0.047).   
hepatotoxicity, as assessed by plasma alanine aminotransferase (ALT), aspartate 
aminotransferase (AST) and alkaline phosphatase (alk phos) levels (Figure 26). The 
dose of 12.
m
m
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Figure 26: PX-866 has modest effects on plasma aminotransferases 
Mice treated as described in “materials and methods.” ALT p=0.0099, n=7; AST 
p=0.0262, n=7; alkphos p=0.8, n=3. * p < 0.05, ** p < 0.01. 
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Figure 27: PX-866 suppresses Ad-5-induced hypertriglyceridemia 
C57BL/6 mice were pretreated with 12.5 mg/kg PX-866 or DMSO before infection 
with replication-deficient Ad-5 and sacrificed on day 4 post infection. Quantification of 
plasma iglyceride (mg/ dl). Each symbol represents one mouse. Horizontal bar is mean 
of the group.  * p < 0.05 compared to Ad-5, vehicle-treated;   # p < 0.05 compared to 
uninfected, vehicle-treated. 
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Discussion:   
 
 Currently, there is no published research demonstrating a relationship between 
the novel PI3K inhibitor PX-866 and hepatic lipid metabolism.  Furthermore, a 
literature search reveals an absence of data and/or study concerning the ability of the 
popular PI3K inhibitors LY294002 and wortmannin to decrease triglyceride.  The 
participation of the PI3K/Akt pathway in insulin-induced SREBP1 expression and the 
inhibition of Ad-5-induced SREBP1 activation by PX-866 observed in our other studies 
prompted the hypothesis that this compound could, like wortmannin and LY294002, be 
used to elucidate the role of the PI3K/Akt pathway in lipid metabolism.  Despite the 
observations by others that PX-866 increases plasma insulin and leads to glucose 
intolerance in mice (335), we were curious to determine if PX-866 would decrease basal 
hepatic SREBP1 and influence systemic lipid metabolism based on our previous 
observation that PX-866 inhibits Ad-5-induced SREBP1 expression and activation.  The 
unexpected increase in plasma glucose in response to PX-866 is perplexing in light of 
observations that PX-866 induced hyperinsulinaemia.  Insulin affects the liver by not 
only inducing increases in SREBP1 leading to increased fatty acid synthesis, but also 
dampens glucose production by the liver (87).  One explanation for our observation 
could be based on the fact that in an hyperinsulinaemic insulin resistant state, such as 
diabetes, insulin does not suppress liver gluconeogenesis (87).  Perhaps this is partially 
responsible for our observation of increased plasma glucose following PX-866 
administration.  Another plausible scenario responsible for the observed increase in 
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glucose could involve the relationship between PI3K/Akt and the Forkhead 
anscription factor FOXO1 and the FOXO1 gene targets phosphoenolpyruvate tr
carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase).  Hepatic PI3K/Akt 
signaling results in the phosphorylation of FOXO1, a phosphorylation event leading to 
subsequent inhibition of the expression of the gluconeogenic genes PEPCK and G6Pase 
(387).  With this in mind, the observed increase in glucose could feasibly be in response 
to hepatic inhibition of PI3K/Akt signaling by PX-866, thus allowing for unchecked 
signaling activation of gluconeogenesis via FOXO1.  Despite the potential explanations 
for this observation, the increase in plasma glucose in response to PX-866 may well 
diminish its potential in the clinic as this effect could disrupt proper systemic glucose 
and lipid metabolism as glucose, like insulin, can activate SREBP1 (87).   
 On the other hand, plasma TG was decreased in PX-866-treated mice.  This was 
accompanied by a trend toward a decrease in hepatic SREBP1 expression.  Presumably 
this is due to the location of hepatic PI3K signaling downstream of glucose and insulin 
signaling in the hepatocyte, an event likely inhibited by PX-866.  Therefore, despite the 
PX-866-mediated increases in plasma glucose that can 1) lead to increases in pancreatic 
insulin secretion and 2) itself activate hepatic SREBP1 expression and activation, the 
outcome of blatant increases in SREBP1 expression and increases in systemic TG were 
not observed in these PX-866-treated mice.  This alludes to the possibility that this 
compound might have a clinical use in treating hyperlipidemia.  Furthermore, the 
absence of frank hepatotoxicity supports this and suggests that the proper dose could 
sidestep even modest increases in hepatotoxicity.  Nonetheless, further investigation is 
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required in this and other in vivo models before speculating as to what lipid-lowering 
benefits PX-866 might have in humans as it is argued that there is no one appropriate 
animal model from which conclusions can be drawn concerning the potential efficacy of 
a compound in humans (388).      
 A possible explanation for decreased SREBP1 and plasma TG upon 
administration of this compound is that a spike in plasma insulin resulting from PX-866 
in mice exhibiting normal plasma insulin prior to treatment can paradoxically reduce 
hepatic fatty acid synthesis.  Previous evidence showed that a transient spike in insulin 
can reduce liver fat mass (389).  It can be assumed that this is a compensatory 
mechanism to safeguard the liver from becoming overstimulated in response to an acute 
spike in insulin.     
 Another interesting observation in this study was the significant increase in 
plasma cholesterol following PX-866 administration.  As mentioned, this increase may 
be due to an increase in HDL, the primary transporter of cholesterol in mice.  
Unquestionably, further investigation of this event is required if PX-866 is ever destined 
for the clinic.  For instance, in other mammals relying on LDL as a TG transporter, 
would PX-866 increase LDL and, in effect, promote atherogenesis?  These questions 
and our observation also prompts the hypothesis that SREBP2 is affected by PX-866 as 
it is the primary SREBP isoform involved in cholesterol metabolism (25).  Further 
experimentation is necessary to determine whether PX-866 can regulate also SREBP2.  
In several organisms, the antiatherogenic action of the statins class of compounds is 
primarily due to decreases in plasma TG (388).  In light of these data, PX-866 could be 
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a beneficial lipid-lowering therapy.  Further extension of our findings is imperative.  In 
conclusion, our data indicate that PX-866 modulates basal lipid metabolism in mice.  
Whether PX-866 will be of clinical value excluding its chemotheurapeutic benefit is 
uncertain at this juncture.     
 
   
 
 
 Chapter 5: Concluding remarks 
 
 
 It is appreciated that abnormal lipid metabolism underlies several disease 
ing diabetes, atherosclerosis, the metabolic syndrome and cancer.  In order 
strategies to treat these diseases, a greater understanding 
echanisms that contribute to aberrant lipid metabolism and subsequent cellular 
perative.  Systemic lipid metabolism depends significantly on proper 
lipid metabolism in the liver, specifically as directed by SREBP.  The SREBP family of 
transcription factors is responsible for the regulation of cholesterol and fatty acid 
biosynthesis in the liver and other tissues.  SREBP proteins respond to and, in effect, are 
regulated by the cellular environment to maintain lipid homeostasis.   
The studies presented here characterize three novel regulators of SREBP1, the 
isoform of SREBP involved in the contol of fatty acid and TG metabolism that 
subsequently impact SREBP1-directed regulation of lipid metabolism.  The second 
study presented here provides evidence that iPLA2 can inversely influence SREBP1.  
Our experiments using the suicide substrate inhibitor of iPLA2, BEL, implicate iPLA2 
catalytic activity in modulating SREBP1.  Furthermore, it can be inferred that iPLA2-
generated products, especially UFA, participate in regulating SREBP1.  An unexpected 
finding in these studies was the effect of iPLA2 on SREBP1 at the level of expression as 
previous research showed a relationship between PUFA and SREBP at the level of 
SREBP processing (39).  Nonetheless, the effect of iPLA2 at the level of expression still 
states includ
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resulted in downstrea scription and at the 
expression level of SREBP1 targets. 
These data allude to the potential targeting of iPLA2 in the clinic.  
Overexpression of iPLA
apoptosis if a thresho
 
m effects at the level of SREBP-mediated tran
2 in hepatocytes could, based on these data, lead to decreased 
SREBP1 activity and subsequent decreases in hepatic TG.  Liver hypertriglyceridemia 
is an etiological player in several diseases such as NAFLD and is one manifestation of 
the metabolic syndrome.  Overexpression if iPLA2 could antagonize the characteristics 
of this syndrome.  Because iPLA2 is involved in a variety of cell types and demonstrates 
diverse cellular roles (see general introduction), overexpression of this enzyme in 
several cell types could prove to be detrimental.  For instance, it has been shown by the 
Tabas group that atherosclerotic plaque stability depends on macrophage foam cell 
survival (24;191;390).  His group determined that macrophage foam cells will undergo 
ld ratio of cholesterol to the glycerophospholipid PC is exceeded 
(390).  With this in mind, inhibition of SREBP1, which facilitates expression of genes 
involved in glycerophospholipid synthesis, by iPLA2 could exacerbate macrophage 
foam cell death by increasing the cholesterol to PC ratio.  In this instance, iPLA2 
inhibition would be the desired regulatory “direction.”  However, inhibition of the 
iPLA2 could prove detrimental, again underscoring the significance of cell context, as
Bao et al, in an extension of previous studies in INS-1 cells that demonstrated that 
iPLA2 overexpression enhanced glucose-induced insulin secretion (190;287), recently 
observed impaired glucose tolerance and decreased insulin secretion in iPLA2 knockout 
mice (187). Thus, while iPLA2 can regulate SREBP1, whether or not a cell or organism 
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benefits from iPLA2 modulation is inherently cell-type specific.  Furthermore it is 
necessary to determine if iPLA2 can modulate SREBP2 as well.  These experiments are 
planned.       
An unexpected discovery during studies that employed iPLA2 overexpression by 
an adenovirus strategy was the ability of replication-deficient Ad-5 to activate SREBP1 
and result in increases in liver and circulating TG in vivo.  This finding has not been 
reported to our knowledge though it is becoming well understood that HCV can 
influence hepatic lipid metabolism (99;349-351;391).  However, our investigation of 
Ad-5 demonstrated its effect is selective for SREBP1, whereas HCV activates SREBP1 
and SREBP2 (350).  Our data indicate that Ad-5 signaling mimics insulin signaling in 
the hepatocyte by activating the PI3K/Akt pathway.  The PI3K inhibitors LY294002 
and PX-866 were able to block activation of SREBP1 by first-generation Ad-5.  This 
study is significant for several reasons.  It characterizes a potential role of viral infection 
in dyslipidemia, fatty liver disease and NAFLD and raises questions concerning the use 
of these vectors to express trangenes in gene therapy as replication-deficient Ad-5 is 
commonly exploited for gene therapy.  It also provides an explanation for the visible 
increase in liver mass of infected C57BL/6 mice other researchers have witnessed 
(personal communication with Gregorio Gil, PhD).  However, it should be noted that all 
effects in response to replication-deficient Ad-5 were transient.  Nonetheless, there is no 
reason to assume that this transient spike in lipid metabolism is precluded from 
affecting other systemic processes, especially those connected to lipid metabolism, 
following this transient spike and once hepatic lipid metabolism has returned to basal 
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condition.  This study was initiated through the rigorous use of controls for several 
initial experiments and therefore highlights the importance of controlling for even the 
“not-so-obvious” aspects of an experiment.  This study also underscores the need for the 
search for “negligible” transgene vectors. HepG2 cells are infected with lentivirus 
indicating that lentiviral strategies may be a more suitable alternative to transgene 
expression; however, these studies have not been performed.  The question remains as 
to whether lentivirus would induce similar effects on hepatic lipid metabolism.  Studies 
using the protocols developed in Chapter 2 to assess hepatic and systemic lipid 
metabolism should be designed to screen for the affects of various viral vectors 
including lentiviruses, other adenovirus serotypes, Ad-5 vectors with different deletions 
and/or additions of the early genes on lipid metabolism.   
It is possible, however, that, in the case of Ad-5 infection, the association of the 
penton base RGD domain with alpha and beta integrins of the hepatocyte is the culprit 
responsible for initiating PI3K signaling leading to modulation of hepatic lipid 
metabolism.  If, indeed, this is the case, infection by internalization of Ad-5 into the 
host cell arguably is not required to impact SREBP1 and lipid metabolism.  Instead the 
mere association of the penton base of Ad-5 with alpha and beta integrins of the host 
cell could be the minimum requirement to induce PI3K activation and hence the 
induction of SREBP1.  Were studies to find that the mere association of the penton base 
with host cell integrins and/or the internalization of the Ad-5 into the host cell to be the 
minimum requirement(s) to induce hepatic lipid biosynthesis, experiments screening for 
the effects of the adenoviral early genes might be unnecessary and irrelevant.  On the 
  164  
other hand, the internalization of Ad-5 into the host cell could be required.  Recent 
evidence from Rogers et al demonstrates that the early gene E4 open reading frame 1 
(E4ORF1) of Ad-36 influences lipid metabolism by inducing adipogenic genes in 3T3-
L1 preadipocytes (358) and therefore prompts speculation as to whether the genetic 
composition of Ad-5 induces the effects presented in Chapter 2.   
The Ad-5 study of Chapter 2 led to another exciting discovery that characterizes 
“chemical” regulation of hepatic lipid metabolism.  Currently, there are only four 
studies in the literature characterizing PX-866.  All of these focus on its efficacy as an 
antitumor agent.  The study detailed in Chapter 4 further characterizes the compound 
and demonstrates its value beyond cancer research.  It is interesting that there have not 
been more studies focused on the potential for PI3K inhibitors to treat hyperlipidemia 
despite their being used to uncover the relationship among insulin, PI3K/Akt and 
SREBP1 biology (62;88).  There is evidence, at least in the case of wortmannin, to 
suggest that the compounds are either unstable and/or induce hepatotoxicity thus 
precluding their clinical value (392).  Despite this, a literature search of the 
contributions of LY294002 and wortmannin to hypotriglyceridemia indicates that area 
is not a focus of current research.  Perhaps systemic administration of a PI3K inhibitor 
would be tantamount to a dose of chemotherapy.  In other words, in vivo PX-866 
treatment might not only attenuate SREBP1 activation, but might prove deleterious to 
other cells in the organism as the PI3K/Akt pathway is critical to cell growth and 
proliferation (318).  Potentially the long-term effects may prove to outweigh the 
benefits of the compound.  For instance, would long-term use of PX-866 lead to bona 
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fide insulin resistance as it has been shown to lead to decreased glucose tolerance and 
hyperinsulinemia (335)?  
On the other hand, it remains tempting to consider the potential for PX-866 to 
treat insulin resistance based on the following:  Insulin resistance is a complex 
pathology.  Diet, plasma glucose, pancreatic insulin secretion, plasma insulin levels and 
relative function or dysfunction of the hepatocyte and its ability to respond to insulin are 
disparate manifestations contributing to the disease.  Nonetheless, a simple truth is that 
there is often hyperactivity of SREBP-mediated transcription due to the 
hyperinsulinemic state of the disease.  Based on this information, it is reasonable to 
speculate that PX-866 could, in a sense, provide a therapeutic “short” in the circuit 
between increased insulin signaling and subsequent SREBP1 activation.  Yet, as 
observed in our study, plasma glucose increased in response to PX-866 treatment 
(Figure 25) potentially due to undampened signaling through FOXO1 to induce 
gluconeogenesis during PI3K/Akt inhibition by PX-866.  Perhaps it is for this reason 
PI3K inhibitors are not used in the clinic to treat dyslipidemia, diabetes and/or other 
disorders of lipid metabolism.  Pioneering the development of PX-866, the Powis group 
attempted to blunt PX-866 induced glucose intolerance and hyperglycemia by 
administering insulin coupled with pioglitazone, a PPARγ agonist and member of the 
thiazolidinedione class of drugs used to treat hyperglycemia in Type 2 Diabetes by 
enhancing peripheral glucose disposal (393), and found that this regimen attenuated PX-
866-induced hyperglycemia (335).  Therefore, before more progress can be made in 
determining the efficacy of PX-866 to treat lipid disorders, extensive review of systemic 
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glucose biology and signaling processes must be implemented while bearing in mind 
that, as the Powis group determined (335), successful use of PX-866 in the clinic may 
require coadministration of other compounds to mitigate the undesired “side effects of 
PX-866.     
And what about the increases in cholesterol upon PX-866 administration 
observed in the study presented here?  Perhaps this is a negligible increase?  Perhaps in 
organisms using HDL and LDL as lipid transporters, there would be a shift from LDL 
to HDL species resulting in a phenotype resistant to atherosclerosis and its 
complications.  However, might the shift favor LDL and thereby promote a 
dyslipidemic phenotype?  Understandably, based on the scarcity of literature 
characterizing this compound and the questions raised by available literature and those 
presented here, further investigation of the effect of this compound on lipid metabolism, 
and in this case on lipoprotein profile, must be explored further to determine whether its 
impact on lipid metabolism will be a benefit or detriment to the host.      
It is interesting to consider that SREBP1 can be influenced by such disparate 
elements: a foreign virus, an enzyme already involved in lipid metabolism and a 
compound destined for chemotherapy.  Certainly the classical feedback mechanisms 
can begin to explain the reason iPLA2 can inhibit SREBP1.  However, why would an 
adenovirus induce SREBP1 and TG synthesis?  Perhaps this Ad-5-induced activation of 
SREBP1 is a mechanism exploited by wild-type adenovirus.  What purpose it serves is 
uncertain.  For example, if the adenovirus needed energy to replicate, it might be 
assumed that the balance would tilt toward beta-oxidation of fatty acids rather than lipid 
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synthesis.  On the other hand, adenoviral replication and the subsequent generation of 
daughter adenoviruses likely depend on lipid synthesis for daughter adenovirues.  In 
this case, SREBP1 activation to promote lipid synthesis for daughter adenoviruses is a 
logical reason for increased SREBP1 activation following adenovirus infection.   Again, 
these studies, while discovering and characterizing novel mechanisms of lipid 
regulation, have raised additional questions that can only be answered by further 
experimentation.  In conclusion, these findings further support the importance of 
SREBP, especially SREBP1, to the regulation of lipid metabolism and characterize 
novel regulatory mechanisms of SREBP1 that, in the case of iPLA2 and PX-866, may 
prove useful in the clinical setting.   
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